ZYLOX TONBRIDGE
INNOVATION FOR QUALITY LIFE

2025
Environmental, Social and Governance Report

Zylox-Tonbridge Medical Technology Co., Ltd.



Contents

About This Report

Information About This Report

This is the fifth Environmental, Social and Governance Report (the "ESG Report") of Zylox-Tonbridge Medical Technology Co., Ltd. ("the Company", "Zylox-Tonbridge" or "we"), aiming to systemically disclose to our stakeholders our sustainable development management approach, practices and performance concerning product research and development ("R&D"), supply chain management, employee management and development, environmental protection and community engagement.

Reporting Scope

This report covers the period from January 1 2025 to December 31 2025, and part of the content can be traced back to previous years or extended to future years. Unless otherwise noted, the key performance indicators ("KPIs") for the environmental aspects in the ESG Report are applicable to the main manufacturing sites and offices of the Company in Hangzhou, Zhuhai, Shanghai, Beijing and Suzhou; the KPIs for social aspects in the ESG Report are applicable to the Company and its subsidiaries.

Reporting Standards

The ESG Report is prepared in accordance with the requirements of Appendix C2 Environmental, Social and Governance Reporting Code (the "ESG Code") to the Main Board Listing Rules (the "Listing Rules") of Hong Kong Exchanges and Clearing Limited (HKEX). Additionally, the report references the "GRI Sustainability Reporting Standards (2021 Edition)" (the "GRI Standards") issued by the Global Sustainability Standards Board (GSSB), the United Nations Sustainable Development Goals (the "UN SDGs"), and key topics covered by the MSCI ESG Ratings.

Reporting Principles

- "Materiality": The ESG Report determines the key ESG topics through stakeholder engagement and materiality assessment during the preparation process.
- "Quantitative": The ESG Report discloses quantitative information on the environmental and social KPIs, supplemented by narrative explanations of their purposes and impacts.
- "Balance": The ESG Report follows the principle of balance to provide an unbiased picture of our ESG performance.
- "Consistency": The ESG Report is the fifth one issued by the Company. Unless otherwise specified, the key indicators and statistical methods are consistent with those used in 2024.

Report Availability

The ESG Report is available for viewing or download on the HKEXnews website (http://www.hkexnews.hk) and the Company's official website (http://www.zyloxtb.com/).

Statement of the Board of Directors

In accordance with the ESG Code, the Board of Directors continues to improve the Company's ESG management framework. The Board is committed to strengthening its oversight, guidance, and engagement in ESG management, and actively promotes the integration of ESG considerations into corporate strategy, major decision-making, and business practices.

Role of the Board

The Board assumes the ultimate responsibility for Zylox-Tonbridge's ESG strategy, management and reporting.
The Board is responsible for continuously overseeing the Company's commitment and performance on key ESG issues, and collaborating with the senior management and the ESG working group to integrate ESG management into internal control, risk management, and business operations. The Board fully understands the current status and progress of the Company's ESG management, makes final decisions on ESG-related issues, and continuously enhances ESG management capabilities.

ESG management approach

The Board closely monitors ESG compliance requirements, emerging trends and peers practices. Taking into account the Company's strategic priorities and key stakeholder concerns, the Board reviews and identifies ESG-related risks and opportunities and defines the Company's ESG management priorities. The Board also reviews and updates the relevant policies and approaches when necessary to ensure the ESG-related management effective. This report presents the progress and performance of the Company's ESG efforts in 2025 and was approved by the Board on March 17, 2026.

Management Message

2025 was a year of progress for Zylox-Tonbridge, as we pursued innovation-driven growth and global opportunities. Guided by our brand philosophy of "Innovation for Quality Life", we remain committed to steady growth in business performance, accelerated international expansion, and further progress in ESG management. From local innovation to global benefit, and from technological breakthroughs to responsible practices, we advanced with conviction and practical action, creating long-term value through high-quality and sustainable development.

Chairman and Chief Executive Officer

Dr. Jonathon Zhong Zhao

Advancing global health through technological innovation. As a leading innovator in China's vascular interventional medical device industry, Zylox-Tonbridge always puts patients first and integrates quality management across all stages of R&D, manufacturing and commercialization. We provide high-quality and affordable innovative products and solutions for patients worldwide, contributing to more equitable and accessible healthcare. In 2025, we launched a series of products including the ZYLOX Mammoth ™ Large-Bore Thrombectomy Catheter, the FALCO ™ Embolization Assist Stent, and the UltraFree® Drug Coated Balloon-BTK. Meanwhile, the ZYLOX Orca ™ Balloon-Expandable Covered Stent, the ZYLOX Otter ™ Thrombectomy Catheter, and the Self-expandable Aneurysm Embolization Device were successfully included in the NMPA's Special Review Procedure for Innovative Medical Devices, contributing to the high-quality development of China's innovative medical device industry.

Joining hands for a shared future. People are Zylox-Tonbridge's most valuable asset. We respect and value every employee, and continue to strengthen our mechanisms for protecting employee rights and interests. We provide all employees equal employment opportunities and broad global development pathways, and are committed to fostering a healthy, safe, equal and inclusive workplace that inspires creativity and strengthens employees' sense of belonging. We always fulfill our responsibilities as a corporate citizen, leverage our expertise as a medical technology company, actively carry out public health education and related initiatives, and participate in community development in diverse ways. At the same time, we actively engage in public welfare initiatives, support the development of a multi-level medical security system, and contribute to improving public health and well-being.

Protecting our planet through green and low-carbon development. 2025 marks the 10th anniversary of the signing of the *Paris Agreement*, as global climate governance enters a critical stage. Zylox-Tonbridge actively addresses climate change, continuously strengthens its climate governance, regularly assesses climate-related risks and opportunities, and steadily enhances its climate resilience. In addition, we continue to strengthen environmental management, improve resource efficiency, and develop eco-friendly modern manufacturing parks, thereby advancing a cleaner and more environmentally friendly operating model and further promoting our green development.

Consolidating the foundation for development through sound governance. Zylox-Tonbridge continues to enhance its corporate governance and compliance management framework across the entire business chain. Guided by high standards of business ethics, we uphold responsible business practices throughout the global operations. We place strong emphasis on ESG governance, closely monitoring global sustainable development opportunities and challenges, enhancing integrity and compliance standards for global operations, and integrating sustainability into corporate strategic decision-making and daily operations. Through these efforts, we continue to promote the integration of corporate governance, environmental protection and social responsibility, providing solid support for the steady operation and long-term sustainable development of our global business.

Embarking on a new journey toward the future. Looking ahead, Zylox-Tonbridge will continue to pursue development with a global vision, enhance value through innovation, and fulfil its mission with a strong sense of responsibility. We will provide higher-quality products and solutions for patients worldwide, and work with all stakeholders to create a healthier and more sustainable future together.

About Zylox-Tonbridge

About Us

Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge", stock code: 2190.HK) focuses on developing, manufacturing, and commercializing innovative medical devices for vascular intervention. Established in 2012, the Company is headquartered in Hangzhou, China, with offices and R&D centers in Zhuhai, Beijing, Shanghai, Suzhou and other locations.

Zylox-Tonbridge has always adhered to the brand philosophy of "Innovation for Quality Life", and is committed to providing patients with high-quality and affordable innovative medical devices and solutions, enabling everyone to enjoy the high-quality life brought by advanced medical technologies. The Company operates two core brands: "Zylox Medical" specializes in peripheral vascular intervention, while "Tonbridge Medical" focuses on neurovascular intervention. In addition, we also have a vascular closure business line.

Zylox-Tonbridge has built a comprehensive product pipeline in vascular intervention. The Company has developed a range of products with independent intellectual property rights, meeting leading domestic and international standards. Backed by innovative designs and reliable quality, these products are well-recognized and trusted in both the Chinese and global markets. By the end of 2025, Zylox-Tonbridge has established a pipeline of 79 products, and our commercialization network now covers more than 80 countries and regions worldwide.

Zylox-Tonbridge remains committed to improving the accessibility of healthcare through technological innovation, while promoting the sustainable development of both the Company and society through responsible business practices.

Core Values

- Integrity
- Responsibility
- Excellence
- Cooperation

Vision and Mission

We are dedicated to building a comprehensive treatment platform for vascular diseases, providing high-quality and affordable medical products for all patients. Regardless of race, age, or wealth, every patient can benefit from the well-being and health brought by Zylox-Tonbridge.

2025 Sustainability Performance Highlights

Business

Revenue amounted to RMB **1.057** billion

Representing a year-on-year increase of **35.1%**

International revenue amounted to RMB **48.65** million

Representing a year-on-year increase of **115.5%**

Net profit exceeded RMB **244** million

Representing a year-on-year increase of **143.7%**

Innovation

R&D investment totaled RMB **247** million

A total of **148** patents were granted

73 invention patents

70 utility model patents

5 appearance design patents

79 products were commercialized or under development

61 products were approved by the NMPA

A total of **10** products were included in the NMPA's Special Review Procedure for Innovative Medical Devices

Social

Total global employees **925**

Average annual training hours per employee reached **11.5** hours

Cumulative donations received by the Zylox-Tonbridge Public Charity Special Fund surpassed RMB **4.5** million

benefiting more than **280** patients

Clinical use of products exceeded **1,100,000** units

Commercial network covering more than **80** countries and regions

Environmental

Total greenhouse gas emissions amounted to **3,849.82** tCO_2e

Total energy consumption amounted to **8,249.95** MWh

Solar photovoltaic power consumption reached **473.27** MWh

Purchased **1,000** Green Electricity Certificates (GECs) for renewable energy

equivalent to a reduction of **570.3** tCO_2e

ESG Ratings and Recognition (selected)

- *2025 Zhejiang Provincial Sci-Tech SME*
  Zhejiang Provincial Department of Science and Technology
- *2025 Hangzhou Enterprise Technology Center*
  Hangzhou Municipal Bureau of Economy and Information Technology
- *First Batch of "New Power" Enterprises*
  Hangzhou Municipal Bureau of Economy and Information Technology
- *2024 Zhuhai Top 100 Innovative Enterprises · Top 100 in Comprehensive Innovation Capability*
  Zhuhai Municipal Bureau of Science and Technology
- *2024 Yuhang District Government Quality Management Innovation Award*
  City Government of Yuhang District, Hangzhou
- *Excellence Award, 2025 Comprehensive Quality Management Knowledge Competition*
  Zhuhai Municipal Administration for Market Regulation
- *"Caring Organization" Title, 2024 "630" Rural Revitalization Initiative*
  Zhuhai Municipal Administration for Market Regulation and the Zhuhai Red Cross Society
- *2024 Outstanding Charity Donation Award*
  Yuhang Charity Union, Hangzhou
- *Data Management Capability Maturity Model (DCMM) Level 3 Certification*
  China Federation of Electronics and Information Industry
- *Top 10 Innovative Cases of Guangdong Science and Technology Service Stations*
  Guangdong Association for Science and Technology
- *2025 Most Valuable Medical Company*
  Zhitong Finance
- *2025 Annual Investment Value Award*
  Gelonghui.com

2024 Zhuhai Top 100 Innovative Enterprises · Top 100 in Comprehensive Innovation Capability

2024 Yuhang District Government Quality Management Innovation Award

"Excellence Award" in Zhuhai 2025 Comprehensive Quality Management Knowledge Competition

"Caring Organization" Title in 2024 "630" Rural Revitalization Initiative

2024 Outstanding Charity Donation Award

2025 Most Valuable Medical Company

2025 Annual Investment Value Award

Sino-Securities ESG Rating A

Wind ESG Rating A

Embracing Innovation Pursuing Excellence

Guided by the philosophy of "Innovation for Quality Life", Zylox-Tonbridge prioritizes clinical needs and addresses to key technological challenges to drive product innovation. Concurrently, we have established a high-standard product quality management system and strengthened our supply chain management capabilities. These efforts help accelerate the translation of innovations into practical applications, enabling us to provide high-quality, accessible innovative medical device products and solutions for patients worldwide. Through these efforts, we continue to improve access to high-quality products for a broader population.

Key Topics

R&D innovation
Quality and safety
Customer benefits and services
Responsible supply chain

SDGs Response

3 GOOD HEALTH AND WELL-BEING
12 RESPONSIBLE CONSUMPTION AND PRODUCTION
17 PARTNERSHIPS FOR THE GOALS

Chapter Story

Innovative Peripheral Vascular Stent Technology Promotes Global Access to Healthcare

Against the backdrop of an aging global population and the rising prevalence of metabolic diseases, Peripheral Arterial Disease (PAD) has emerged as a growing global health challenge. In clinical practice, the treatment of complex lesions and the risk of restenosis continue to create significant unmet needs, driving demand for peripheral drug-eluting stents that can deliver both safety and sustained efficacy. This also sets higher standards for innovation in peripheral vascular intervention.

To address global PAD treatment needs and clinical challenges, Zylox-Tonbridge developed the ZENFLEX ™ Pro Peripheral Drug-Eluting Stent System. Featuring an open helical structure and segmented micromesh design, the product combines flexibility with strong radial support to adapt to complex peripheral vascular anatomies. Additionally, its polymer-free paclitaxel coating helps maintain vessel patency, providing improved and more durable clinical outcomes for PAD patients worldwide.

In October 2025, the ZENFLEX ™ Pro Peripheral Drug-Eluting Stent System received registration approval from the Brazilian Health Regulatory Agency (ANVISA), marking an important milestone in the product's international market access. Furthermore, as the world's third-to-market peripheral drug-eluting stent, ZENFLEX ™ Pro had previously obtained CE certification in the European Union in October 2020 and has been successfully commercialized in Europe.

Built on innovation and guided by a global vision, Zylox-Tonbridge has been expanding its global market footprint. The Company has successfully commercialized 29 products across 40 countries or regions, including European nations such as France, Germany, and Italy, as well as markets in South America like Argentina and Brazil, and the Middle East such as the United Arab Emirates. Meanwhile, we are applying for registration of more than 50 products in over 34 countries and regions, promoting broader access to high-quality medical solutions and contributing to global health equity through our innovation in medical technology.

In 2026, we announced a strategic investment in Optimed Medizinische Instrumente GmbH ("Optimed"), a German medical technology company specializing in minimally invasive vascular and urological interventions. By integrating its established capabilities in R&D, manufacturing, and commercialization, we have strengthened our foundation for accelerating the global expansion of our innovative products.

Reinforcing the Foundation for Innovation

Innovative Achievements, Safeguarding Patient Health

Driven by differentiated innovation and lean manufacturing, Zylox-Tonbridge has established a comprehensive product portfolio covering neurovascular intervention, peripheral vascular intervention, and vascular closure, providing patients with high-quality and affordable innovative medical devices and solutions worldwide.

In the neurovascular intervention field, the Company offers a portfolio of core products, including the Tonbridge Thrombite® Clot Retriever Device and the Tonbridge Kylin ™ Flow Diverter, providing solutions across key clinical areas such as ischemic stroke, hemorrhagic stroke, intracranial stenosis, intracranial access, and carotid artery stenosis.

In peripheral vascular intervention, the Company develops a range of products, including the UltraFree® Drug Coated PTA Balloon Catheter, the ZYLOX Swan® Endovenous Radiofrequency Ablation System and the ZYLOX Octoplus® Retrievable Inferior Vena Cava Filter, covering eight major clinical areas, including peripheral arterial disease, lowerlimb varicose veins, and thrombosis management.



INNOVATION
FOR QUALITY LIFE

In 2025, the Company launched a series of differentiated products, including the ZYLOX Mammoth ™ Large-Bore Thrombectomy Catheter and the FALCO ™ Embolization Assist Stent. Simultaneously, several of our products, such as the ZYLOX Orca ™ Balloon-Expandable Covered Stent, the ZYLOX Otter ™ Thrombectomy Catheter, and the Self-expandable Aneurysm Embolization Device, have successfully been included in the NMPA's Special Review Procedure for Innovative Medical Devices.

To date, the Company has 79 products, including those marketed and under development, 61 of which have received NMPA approval, and a total of 10 products have been included in the NMPA's Special Review Procedure for Innovative Medical Devices.

ZYLOX Mammoth ™ Large-Bore Thrombectomy Catheter Approved for Market Launch by NMPA

In August 2025, the ZYLOX Mammoth ™ Large-Bore Thrombectomy Catheter received go-to-market approval from the NMPA. As China's first large-bore aspiration catheter specifically designed for high-burden thrombus, this product features an innovative flared tip design combined with a flexible, kink-resistant shaft. It enables safer and more efficient removal of high-burden thrombus from large-diameter vessels, targeting the clinical need for treating complex thrombotic lesions. By addressing clinical needs in the treatment of complex thrombotic lesions, this innovation expands access to high-quality treatment options for physicians and patients and supports improved treatment outcomes in deep vein thrombosis treatment.

New Products Included in the NMPA's Special Review Procedure for Innovative Medical Devices (In Development)

The ZYLOX Orca ™ Balloon-Expandable Covered Stent is indicated for the treatment of stenotic and/or occlusive lesions in the common and external iliac arteries. ZYLOX Orca ™ Balloon-Expandable Covered Stent utilizes exclusive high-rigidity stent material to enhance radial support. Concurrently, it features a dual-structure design combining a TPU elastic sleeve with a pillow-shaped balloon, which synergistically helps improving device stability during delivery. With a covered stent length of up to 108 mm, the system enables single-stent coverage of diffuse lesions, reducing the need for overlapping implantation and supporting procedural safety and long-term vessel patency.

ZYLOX Otter ™ Thrombectomy Catheter is indicated for percutaneous intraluminal removal of acute deep vein thrombosis in the lower extremities. As the world's first lightweight disposable interventional device to integrate thrombolysis, mechanical thrombus fragmentation, and aspiration into a single system, it delivers high thrombus removal efficiency while reducing intraoperative blood loss. In addition, its lightweight system design reduces reliance on a large console, offering advantages in cost-effectiveness and convenience, and is expected to expand the access to peripheral thrombosis intervention treatment in primary healthcare institutions.

The Dual-Layer Micromesh Carotid Stent is designed for the treatment of atherosclerotic carotid stenosis. Its unique connecting structure secures adhesion between the two stent layers. Its dual-layer mesh design combines coarse and dense mesh configurations, balancing radial support, plaque coverage, and flexibility. Additionally, the stent features full-body radiopacity, supporting repositioning and resheathing, thereby improving intraoperative maneuverability and deployment accuracy.

Innovative Medical Device Certification



Innovative Medical Device Certification



Innovative Medical Device Certification

We are dedicated to enhancing global access to healthcare and improving patients' lives through our high-quality medical products and innovative solutions. During the reporting period, we accelerated the global expansion of high-quality products and further expanded access to innovative treatment solutions in international markets. In 2026, we announced a strategic investment in Optimed, a German medical technology company. This move further strengthened our global operational network and expanded access to high-quality medical solutions for patients worldwide. Through these efforts, we continued to support more sustainable and inclusive global healthcare development.

Strategic Investment in Optimed to Expand Global Footprint

In January 2026, Zylox-Tonbridge announced the signing of an agreement with Optimed, a German medical technology company, marking a milestone in Zylox-Tonbridge's globalization. By integrating Optimed's established capabilities in R&D, manufacturing, and commercialization, we will further expand our presence in the European and other international markets, accelerating the global availability of our innovative products. Leveraging the synergies between our manufacturing bases in China and Germany, we continue to enhance our global operational and delivery capabilities, improving access to high-quality medical solutions for patients worldwide.

To strengthen collaboration between the two sides, Zylox-Tonbridge and Optimed jointly hosted a training and exchange program in Hangzhou under the theme "Sailing Forward with Synergy, Win-Win for the Future". Nearly 50 core team members from both companies participated, engaging in in-depth discussions across areas including R&D, manufacturing, regulatory affairs, and commercialization. This program further laid a solid foundation for the two companies to jointly expand access to healthcare solutions in global markets.

Cutting-edge Research, Expanding Technological Boundaries

The Company actively promotes innovation by strengthening R&D capabilities and product portfolio, thereby contributing to technological advancement in the industry and the development of clinical applications. In 2025, Zylox Medical established a dedicated sustainable product R&D function, focusing on the development of biodegradable and bioresorbable materials and exploring the integrated application of environmentally friendly materials to support the green transformation of our products. Meanwhile, Tonbridge Medical also initiated research on sustainable alternative materials for its core products, aiming to reduce the full lifecycle carbon footprint while maintaining clinical safety and high product performance.

Sustainable Alternative Material R&D Project for Microcatheter

In May 2025, Tonbridge Medical launched an R&D project on sustainable alternative materials for microcatheter to enhance product safety and environmental performance at the source. Compared with conventional materials, the new material solution is expected to reduce environmental impact and energy consumption during production, thereby reducing carbon footprint, while its recycling potential helps reduce the burden of waste disposal and supports improved environmental performance across the product lifecycle.

Simultaneously, we have established a collaborative R&D ecosystem, working with leading medical institutions in China to advance medical technology development and innovation. This collaboration supports the continued evolution of vascular interventional therapies toward more precise and refined treatment and broader clinical applications. During the reporting period, we collaborated with leading hospitals, including the First Affiliated Hospital of Chongqing Medical University, the First Hospital of China Medical University, the First Affiliated Hospital, Zhejiang University School of Medicine, and Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, on multiple R&D projects. Additionally, we advanced nearly 50 externally collaborated research projects, including key initiatives such as the Hangzhou High-Quality Development Special Project for the Biomedical Industry and the mid-term evaluation "Pioneer and Leading Goose + X" program of Zhejiang. These efforts supported the translation of research outcomes into practical applications and contributed to industry development.

R&D Management

R&D System

The Company places product R&D at the core of its long-term development and sustainable value creation. Driven by clinical needs, we continuously strengthen our R&D capabilities and management system, advance product innovation, and support the efficient translation of new products into clinical use. We have established and implemented management systems such as the *Product Design and Development Management Regulations*, the *Design and Development Review Committee Operating Procedures*, and the *Risk Management Control Protocol*. Relying on the advantages of our four major R&D and manufacturing technology platforms—the Balloon Forming and Manufacturing Platform, the Catheter Forming and Manufacturing Platform, the Catheter Braiding and Coiling Development and Manufacturing Platform, and the Stent Forming and Technical Processing Center—we have expanded the differentiated and innovative product pipelines. Leveraging our core technological capabilities, we improve R&D and operational efficiency while ensuring consistent quality. Additionally, the Company has strengthened its R&D capabilities through digital transformation, enhanced collaboration mechanisms, talent development, and improved incentive system.

Digital Transformation

We continue to advance digital R&D management by leveraging an intelligent platform to streamline development process. Through ongoing system optimization and new module development, we further enhance standardization and improve operational efficiency. During the reporting period, we introduced AI technology to support research and analysis, including global medical technology insights and the analysis of market and technology trends. These efforts helped accelerate the overall development process.

Collaboration Mechanisms

We have established a regular cross-functional coordination mechanism across R&D, regulatory affairs and operations to strengthen project management, improve collaboration efficiency, and enable the timely resolution of key issues throughout the development process. Additionally, we have established a knowledge base covering key areas such as material selection, structural design, animal studies, process design, and clinical applications, providing strong support for R&D activities.

Talent Development

We continue to invest in R&D resources and maintain long-term partnerships with top-tier universities to attract high-quality talent to further strengthen our innovation capabilities. By the end of the reporting period, among the Company's core R&D employees, those with a bachelor's degree had reached 92%, while those with a master's degree or above had exceeded 47%. We also place great emphasis on enhancing the overall competence and professional capabilities of our R&D teams. During the reporting period, we focused our training on R&D standardization, understanding of international market requirements, and the application of intelligent tools. We developed the Practical Guide to the Design and Development Process and delivered targeted programs, including training on international medical device regulations and AI-enabled R&D. These efforts help foster a global development perspective and promote the integration of AI across the R&D lifecycle to enhance innovation efficiency.

Incentive System

We have established the *R&D Project Incentive Policy* to provide clear incentives across key stages of product development, supporting a more standardized incentive framework. During the reporting period, we updated the *R&D Project Innovation Incentive Guidelines* to further boost the innovation motivation among the R&D team and promote the translation of innovative outcomes. Additionally, we have introduced various incentive awards, including the Project Innovation Award, the Project Empowerment Award, and the Patent Innovation Incentive, to fully recognize the dedication and contributions of our R&D employees.

Uniting Strength and Expertise to Drive High-Quality R&D

In 2025, the Company developed the *Practical Guide to the Design and Development Process*, systematically mapping key milestones and effective solutions across the design and development lifecycle to further strengthen high-quality R&D. We also delivered targeted training combining guide interpretation with practical case analysis to strengthen participants' ability to apply standardized processes and address complex R&D challenges.

In addition, we established an internal knowledge-sharing platform to promote cross-functional collaboration and knowledge exchange. We also continued to enhance our product development knowledge base by improving content, information structure and search functions, supporting more efficient experience sharing across projects and strengthening R&D efficiency and team capabilities.

R&D Ethics

The Company is committed to ethics and compliance in R&D, strictly adhering to applicable requirements, including the *Technical Guidelines for Review of Animal Testing Research on Medical Devices*, the *Regulations on the Administration of Laboratory Animals*, and the *Quality Management Measures for Laboratory Animals*. We have established the *Management System for Animal Testing Planning and Execution Activities* to standardize the relevant research processes. We also require all animal study protocols to comply with the 3R principles of "Replacement, Reduction, and Refinement" and obtain review and approval from the Institutional Animal Care and Use Committee (IACUC).

During the reporting period, we also introduced biomimetic models and adopted in vitro simulation testing methods, reducing reliance on animal studies while maintaining the scientific rigor of our R&D testing. In addition, the Company collaborates with third-party animal study centers that possess the *Certificate of Recognition for Experimental Animal Institutions* and are recognized by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) to ensure the safety and efficacy of animal studies. We also conduct regular on-site audits of our partner institutions to ensure ethical compliance and scientific validity of animal studies.

Clinical Trial Management

The Company recognizes that clinical trials play an essential role in translating R&D outcomes into clinical applications. We are committed to upholding compliance, scientific rigor and humanistic care throughout the clinical trial process, in order to safeguard the rights of participants. We strictly adhere to regulations such as the *Regulations for the Supervision and Administration of Medical Devices* and the *Good Clinical Practice for Medical Devices*. We have also established procedural documents such as the *Clinical Department Project Management Regulations,* the *Routine Audit Procedures for Clinical Trials*, and the *Writing and Review of Clinical Trial Protocols*.

During the reporting period, we updated relevant systems and procedural documents, including the *Key Points and Determination Principles for Medical Device Clinical Trial Inspections* and the *Post-Market Clinical Follow-up Management Regulations*, to further strengthen the clinical trial governance. We attach great importance to the rights and privacy of trial participants, and strictly safeguard their rights to be fully informed. In clinical trial-related contracts or agreements, confidentiality obligations are explicitly stipulated for investigators, clinical trial service providers, sponsors and other relevant parties to ensure the strict protection of paticipants' personal information and privacy. In addition, we provide clinical trial liability insurance for study participants, with clearly defined coverage, to protect their rights and well-being throughout the trial process.

We continuously improve our end-to-end clinical trial management by defining clear requirements across key stages, including study design, initiation, conduct, and evaluation. We conducted regular clinical trial monitoring, and performed on-site audits and quality controls, either internally or through third-party organizations at key project milestones or as needed, ensuring trial compliance and data integrity. During the reporting period, we conducted a total of 36 clinical audits and no significant clinical trial issues were identified. In addition, to enhance the professional capabilities and compliance awareness of clinical project personnel, we delivered over ten specialized training sessions focused on key topics such as policy and regulatory requirements, clinical project workflows, data management, and trial participant follow-up management.

Industry Exchange

Progress in the healthcare industry has never been a solitary journey, but a collaborative endeavor shared by physicians, practitioners, and innovators. Guided by the core value of "Excellence" and "Cooperation", we leverage our technological advantages and resource to actively build an open and inclusive platform for cooperation and exchange. We share cutting-edge scientific research achievements, clinical practice experiences, and innovative technological solutions with our industry partners, joining hands to drive advancements in medical technology.

Zylox-Tonbridge Academic and Innovation Exchange Platforms

Zylox Innovation Lab

Zylox Innovation Lab, backed by Zylox Medical, targets medical professionals and related partners, by building a multidimensional platform for academic exchange, skill development, medical-engineering integration, patient education, and social responsibility initiatives, to provide higher quality medical services to physicians and patients across China.

Tonbridge Insight Hub

Leveraging the innovative neurovascular intervention product line, Tonbridge Insight Hub stays abreast of international cutting-edge technologies and product advancements, expanding from top-tier hospitals to grassroots healthcare institutions while promoting the standardized and equitable delivery of neurointerventional procedures across all levels of healthcare.

Innovation Workshop

Focusing on product innovation driven by medical-engineering integration, the Innovation Workshop leverages major academic conferences across China to host expert-engineer dialogue sessions. These forums foster direct communication between experts and R&D teams, enabling joint exploration of cutting-edge solutions to address unmet clinical needs.

Technical EmpowerCamp

Through our Technical EmpowerCamp, we promote advanced medical concepts and standardized surgical procedures, facilitating the dissemination of high-quality medical technology and services to the grassroots and promoting the regional healthcare equalization, and strengthening the clinical skills training for young physicians.

Zylox Innovation Lab: Driving Industry Progress through Expertise and Responsibility

Zylox Medical has built a peripheral intervention academic exchange platform based on the Zylox Innovation Lab. Since official launch in 2023, Zylox Innovation Lab Wechat official account has been dedicated to the field of peripheral interventions. Focusing on health education, industry trends, and academic exchange, we have published 310 educational and informational articles. We employed engaging narratives to make scientific knowledge accessible, thereby fostering public awareness of evidence-based health management.

We enhanced Zylox Innovation Lab official account in 2025 and introduced a redesigned mini-program in January 2026, to establish a more efficient and accessible vertical academic exchange ecosystem and inspire vitality of academic innovation. This platform has reached over 1,400 industry professionals, which supports the growth of mid-career medical workers and cultivates talent across the sector. In addition, Zylox Innovation Lab maintained integrated online and offline engagement, leveraging digital tools to enrich offline academic events and clinical experience exchanges related to peripheral interventions. This enhanced the efficiency of industry practice and exchange, facilitating deeper integration between clinical techniques and practical application.

We embraced our responsibility by actively participating in academic exchange activities within the field of vascular intervention in China and globally. Collaborating with industry partners, scholars, and experts worldwide, we shared innovative concepts, explored cutting-edge technologies, and discussed the latest industry trends to contribute to high-quality development in the sector. During the reporting period, we participated in several industry events of academic exchange, including the 16th China Endovascular Course (CEC 2025), the 2025 Oriental Conference of Interventional Neurovascology (WLNC&OCIN 2025), the Pan Arab Interventional Radiology Society (PAIRS 2025), the Live Interventional Neuroradiology & Neurosurgery Course Paris 2025 (LINNC PARIS 2025), the 2025 Cardiovascular, Interventional Radiological Society of Europe (CIRSE 2025), and the 52th Annual Symposium on Vascular and Endovascular Issues (VEITH 2025).

Tonbridge Medical Showcased at the LINNC PARIS 2025

From June 2 to 4, 2025, the LINNC PARIS 2025 convened in Paris. As one of the world's most influential academic conferences in neurointervention, this year's event once again brought together leading experts worldwide to explore cutting-edge technologies and clinical innovations.

During the conference, Tonbridge Medical showcased its core products, including the Kylin ™ Flow Diverter, the Thrombite ™ Clot Retrieval Device, and the Gekko ™ Detachable Coil System, presenting our comprehensive solutions to neurointervention experts worldwide. The display attracted experts and clients from multiple countries and regions for in-depth discussions. Our products received positive feedback from experts for their innovative design, operational performance, and quality, reflecting strong professional recognition. Building on our success at LINNC PARIS 2025, we have been accelerating our globalization strategy, by continuously expanding international exchange channels, and deepening our global collaborative ecosystem.



Zylox Medical Participated in the CIRSE 2025

As one of the world's most influential interventional conferences, the CIRSE 2025 was successfully held in Barcelona from September 13 to 17, 2025. At the conference, Zylox Medical highlighted its comprehensive solutions for peripheral vascular interventions, showcasing star products including the ZYLOX Unicorn® Vascular Closure Device, the ZYLOX Mammoth ™ Large-Bore Aspiration Catheter, and the ZYLOX Eagle® Aspiration System. Together with global leading experts and industry peers, we exchanged the latest interventional treatment concepts and cutting-edge technologies, jointly exploring future directions in peripheral vascular disease treatment. The participation in CIRSE 2025 demonstrated Zylox Medical's innovative achievements in the peripheral vascular field and laid a solid foundation for the Company's further expansion into international markets and for strengthening academic exchanges with experts worldwide.


The Company places strong emphasis on industry collaboration and actively participates in industry associations. Leveraging these association platforms, we promote the co-creation of an innovation ecosystem and work with industry partners to support the sector's high-quality and sustainable development. As of the end of the reporting period, the industry associations we have joined are as follows:

Engagement in Industry Associations	Association Position
China Association for Medical Devices Industry	Member
Zhejiang Provincial Association for Medical Equipment Industry	Council Member
Shen Kuo Science Kommunikation Foundation	Council Member
Guangdong Precision Medicine Application Association	Council Member
Guangdong Council for the Development Promotion of Small and Medium Enterprises	Member
Biopharmaceutics Industry Association, Yuhang District, Hangzhou	Vice President
Yuhang Charity Union Hangzhou	Vice President
Zhuhai Medical Device Industry Association	Vice President
Hangzhou Healthcare Security Research Association	Council Member
Zhuhai Science and Technology Development Promotion Association	Council Member
Zhuhai High-tech Zone Biomedicine and Medical Device Association	Council Member
Zhuhai Association for Quality	Standing Council Member
Zhuhai Enterprises Association for Foreign Economic Cooperation	Vice President
China Neuro-Medical Innovation and Translation Alliance	Gold Partner

Strengthening Quality Control

Quality Management System

As we strive to provide safer, more reliable, and higher-quality products to patients worldwide, we have established an integrated quality management system that encompasses quality governance, system certifications, and external audits. The Company complies with the *Regulations for the Supervision and Administration of Medical Devices*, the *Good Manufacturing Practice for Medical Devices*, and the *Provisions for Medical Device Registration and Filing*, as well as relevant national and regional laws and regulations such as REGULATION (EU) 2017/745, Brazilian regulations RDC No.665/2022, RDC No.23/2012, and RDC No.67/2009. Based on these regulations, the Company has formulated a series of procedural documents, including the *Control Procedure for Monitoring and Measurement of Products*, the *Quality Record Control Procedure*, and the *Risk Management Control Procedure.* During the reporting period, in response to the new version of the *Good Manufacturing Practice for Medical Devices* issued by the NMPA (Announcement No. 107 of 2025), we conducted a comprehensive review and benchmarking analysis, and iteratively upgraded the relevant quality management documents. We revised several management systems, including the *Quality Manual* and the *Management Procedures for Change and Control*, to further refine quality management standards and processes. Meanwhile, we organized targeted training on the updated regulatory requirements to enhance employees' understanding of compliance expectations and execution capabilities, ensuring the effective execution of all quality control measures.

We persistently pursue the certification of the product quality management system to ensure the standardization and effectiveness of the internal management system. During the reporting period, our Hangzhou and Zhuhai bases have both obtained ISO 13485 Medical Device Management System certification and MDSAP certification, with a coverage rate of 100%. Concurrently, we continuously optimized management processes and enhanced quality control measures through third-party independent perspectives.

We regularly underwent comprehensive audits of our quality management system by external authorities, including the National Medical Products Administration, the Zhejiang Provincial Drug Inspection Center, and the Yangtze River Delta Center for Medical Device Evaluation and Inspection of NMPA. During the reporting period, the Hangzhou and Zhuhai bases collectively received and passed 27 external quality audits. Through our exceptional quality management system and high-quality products, we were honored with the "Government Quality Management Innovation Award" from the Yuhang District Government of Hangzhou and the "Excellence Award, 2025 Comprehensive Quality Management Knowledge Competition" from the Zhuhai Municipal Administration for Market Regulation.

Zylox Medical
ISO 13485 Medical Device Management System Certification Certificate

Tonbridge Medical
ISO 13485 Medical Device Management System Certification Certificate



Zylox Medical
MDSAP Certification Certificate

Tonbridge Medical
MDSAP Certification Certificate

Full Lifecycle Quality Management

We always prioritize product quality and safety, continuously strengthening quality control across the entire product lifecycle, covering R&D design, incoming material management, manufacturing, product testing and traceability, and recall management, to ensure the consistent application of rigorous quality standards.

R&D Design

During the product R&D and design phase, we adhere to clinical value and patient safety as the core principles, integrating applicable domestic and international medical device quality, safety, and regulatory requirements throughout the entire design and development process. Through design reviews and risk management mechanisms, we identify and control potential risks at an early stage, optimize product design, and continuously enhance product performance, clinical compatibility, and patient safety.

Incoming Material Control

We continuously strengthen supplier qualification standards. Based on the risk level of materials, we implement differentiated incoming material inspection procedures to ensure that all incoming materials meet the manufacturing quality requirements. In accordance with the requirements of the ISO 13485 quality management system requirements, we conduct audits of both tier-one and tier-two suppliers covering production equipment, manufacturing processes, and finished-product delivery, as a comprehensive assessment of their quality control capabilities, to ensure the consistency and reliability of supplied products. Furthermore, we require key material suppliers to sign the *Quality Assurance Agreement*, clarifying and reinforcing their quality responsibilities.

Lean Manufacturing Management

We adopt lean manufacturing practices, actively introducing automated manufacturing technologies to ensure the stability and consistency of product quality. During the reporting period, we introduced automated equipment and technologies such as automatic packaging machines to ensure product appearance and labeling quality while significantly reducing labor intensity for relevant positions. At the same time, we regularly conduct comprehensive reviews and evaluations of manufacturing processes to identify gaps and opportunities for optimization in manufacturing techniques, and continue to advance process improvement initiatives. In addition, we have carried out a number of projects, including upgrades to the precision cutting and processing technology for coils. We have also provided frontline employees with training to enhance lean manufacturing skills and awareness, strengthening their understanding of standardized operations and continuous improvement, and encouraging broad employee participation in process optimization.

Manufacturing Environment Management

We fully recognize the impact of manufacturing environment and equipment stability on product quality. During the reporting period, we commissioned third-party professional organizations to conduct comprehensive inspections of the cleanroom environments at our Hangzhou and Zhuhai bases, and all results met relevant standards. We strictly manage production equipment in accordance with core principles such as safety, error prevention, and contamination prevention, and conduct regular equipment maintenance and calibration to ensure that manufacturing equipment is always in optimal operating condition, thereby helping ensure the stability and consistency of product quality.

Product Testing

We have established a comprehensive, end-to-end product testing system to ensure that all products meet quality requirements. Both our Hangzhou and Zhuhai bases have established standardized product safety laboratories, among which the Zhuhai base laboratory has obtained CNAS certification. Our testing capabilities cover physical, chemical, and biological testing items, which can meet the testing needs of all stages, including product performance testing, in-process inspection, and final product release inspection, providing technical support for product quality control. We have also developed a systematic product quality inspection plan that defines testing standards and procedures for various product categories. Additionally, we handle non-conforming products in accordance with the *Non-conforming Product Control Procedure* to ensure the rigor and effectiveness of quality control.

Traceability and Recall

We strictly comply with applicable laws and regulations such as the *Provisions for Medical Device Adverse Event Monitoring and Re-evaluation*, and have established institutional documents including the *Advisory Notice and Adverse Event Reporting Procedure*, the *Feedback Control Procedure,* the *Domestic Medical Device Adverse Event Monitoring, Evaluation, and Product Recall Management Regulations,* and the *Brazil Adverse Event Handling System*. These documents define standardized operating procedures and responsibilities for product recalls. During the reporting period, we introduced additional recall procedures for different countries and regions, including the *Regulations on Monitoring, Assessment, and Recall Management of Adverse Events for Medical Devices in South Korea* and the *Regulations on the Management of Adverse Event Reporting in the Republic of Kazakhstan*, to ensure timely and standardized response to product risks in different regions. During the reporting period, the Company did not initiate any product recalls due to safety and health reasons.

Embedding a Quality-Oriented Culture

The Company embeds a quality-oriented culture by strengthening policy and regulatory communication, establishing a comprehensive quality knowledge base, and enhancing quality training for employees. We foster a strong quality culture that encourages broad participation, while extending quality principles to supplier management. Through these efforts, we embed quality principles across the value chain and improve the quality management standards.

Interpretation of Policies and Regulations

The Company places great importance on policy developments, closely tracks and analyzes relevant laws and regulations in the regions where it operates. We regularly organize internal sharing sessions and regulatory interpretation training to ensure that all employees stay informed of the latest compliance requirements and industry trends in a timely manner.

Knowledge and Experience Sharing

We have established a quality issue knowledge base to document quality issues identified during past testing and their corresponding solutions, facilitating quick access to historical data and analytical results across departments and strengthening the ability to identify and manage potential risks.

Enhancement of Professional Competencies

We regularly conduct multi-level and diverse training activities, including monthly internal training sessions within the Quality Department, external specialized quality training, and general courses on quality management systems. These cover topics such as domestic and international medical device regulations, foundational knowledge of quality management, microbiological principles, and cleanroom SOPs. During the reporting period, the Company organized over 150 quality training sessions, further elevating employees' professional expertise and awareness of quality responsibilities.

Empowerment of Suppliers

We provide specialized training to suppliers to communicate product quality standards and requirements. Additionally, through ongoing engagement and experience sharing, we support suppliers in fully understanding and implementing quality control requirements, thereby driving collaborative improvement in quality management across the supply chain.

Service Optimization

Customer Service Management

The Company adheres to a customer-centric service philosophy. Through multiple channels such as hotlines, emails, and on-site visits, we actively listen to customer needs and place great emphasis on analyzing customer feedback to improve our services. This enables us to continuously enhance service experience and elevate customer satisfaction. We have established internal regulations and procedures, including the *Customer Complaint Management Policy,* the *Domestic Customer Complaint Handling Management Regulations*, and the *International Customer Complaint Handling Management Regulations.* These procedures clearly define complaint handling and product compensation service processes, ensuring comprehensive protection of customer rights and interests.

During the reporting period

Complaints received

59

Response rate

100%

Complaint resolution rate

100%

Customer Compliant Email
swb@zyloxmedical.com

Customer Complaint Handling Commitment
Respond within 24 hours, and provide a resolution plan within 48 hours

Customer Complaint Handling Process

Quality Management Department
Organize meetings, make initial judgment, designate responsible person for cause investigation, and confirm the return of products involved in the complaint

↓

Marketing Department
Track and report investigation results

↓

Sales Department
Notify the complainant of the investigation and handling results

Product Compensation Handling Process

Complainants
Apply for compensation for not-for-sale products

↓

Commerce Department
Review channel-related information

↓

Warehousing Department
Arrange the shipment of products as compensation to relevant distributors

To address the diverse needs of global customers, the Company provides regular customer service training for employees to support consistently high service standards across different markets. For the Chinese market, we focus on a dedicated "Innovation Camp" training program for new employees. The program covers foundational medical knowledge and operational workflows, supporting enhancing employees' professional capabilities and customer service skills. For the international market, we organize training sessions covering product-specific knowledge, cross-cultural communication, business document processing procedures, international industry regulatory frameworks, and standard operating procedures (SOPs). These training programs strengthen the professional competence, cross-cultural communication skills, and operational service capabilities of the international customer service team, supporting the delivery of high-quality international customer service.

Distributor Management

The Company places great importance on distributor management and has established standardized admission and evaluation mechanisms for distributors. We verify the qualifications of prospective distributors, including business licenses, operating permits, filing certificates, and other relevant credentials, while also conducting background checks to strengthen partner due diligence. For existing distributors and agents, the Company manages partnerships in accordance with internal policies such as the *Domestic Distributor Management Standards* and the *International Agent Management Standards*, continuously advancing the standardization and systematization of partnership management. During the reporting period, we conducted audits of distributor operations with a focus on contract compliance and the accuracy of procurement, sales, and inventory records, covering more than 400 distributors in total. All results met relevant management requirements.

We also support distributors in enhancing their professional service capabilities through a range of initiatives. The 2025 Zylox Medical National Channel Development Forum and the 2025 Tonbridge Medical National Channel Development Forum served as platforms to bring together nearly 500 distributor partners for in-depth dialogue, experience sharing, and closer collaboration. In addition, we organized specialized training programs, including product application guidance, to further strengthen distributors' product knowledge and practical application capabilities.

Furthermore, we conduct annual distributor satisfaction surveys, inviting distributors to assess our performance across dimensions such as product quality, business collaboration, and customer service. These surveys help us better understand partner needs and identify opportunities to further improve collaboration.

2025

250

domestic distributors participated in the survey

Distributor satisfaction scores for both Zylox Medical and Tonbridge Medical reaching

96 or above out of 100

2025

Conducting a satisfaction survey targeting international customers, and customer satisfaction scores for both Zylox Medical and Tonbridge Medical reached

93 or above 100

Building a Resilient Supply Chain

Supplier Management

The Company recognizes that supply chain resilience and sustainability as important foundations for stable business operations. We implement a tiered and categorized supplier management approach and have established policies, including the *Supplier Management Policy* and the *Indirect Procurement Management Policy*, to clearly define requirements for supplier onboarding assessment, performance evaluation, and exit management, thereby building a secure, stable, and efficient supply chain management system.

Supplier Onboarding Assessment

In accordance with internal evaluation systems and standards such as the *Supplier Admission Assessment Form*, we conduct comprehensive assessments of suppliers across multiple dimensions, including qualifications, production capacity, product and service quality, and material performance, and require the submission of relevant supporting documents. In addition, on-site audits are conducted for newly introduced suppliers of key materials to ensure compliance with the Company's standards.

Supplier Performance Evaluation

An annual evaluation plan is established in line with requirements such as the *Supplier Evaluation Criteria*. Each year, procurement engineers and Supplier Quality Engineers (SQE) assess suppliers across five dimensions: quality, delivery, cost, service, and manufacturing environment. Supply chain management personnel are responsible for collecting and archiving evaluation results to further enhance supplier management effectiveness. During the reporting period, we conducted annual audits of 204 material and key consumable suppliers, achieving a pass rate of 99.5%.

Supplier Exit Management

Where quality non-conformities are identified in supplied products, the Company promptly issues non-conformance reports, notifies the relevant suppliers, and requires them to investigate the causes and implement corrective actions. For suppliers with repeated non-conformities, the Company applies measures such as warning letters, time-bound rectification, and ongoing follow-up on the implementation of corrective actions. Suppliers that fail to complete rectification within the prescribed timeframe or continue to experience quality issues are subject to supplier exit procedures in accordance with internal management requirements.

Adhering to the philosophy of "win-win cooperation and coordinated development", we proactively share our management experience and operational practices, as well as high-quality resources, with our supplier partners to empower their growth and enhance the overall performance of the supply chain. As of the end of the reporting period, the Company had a total of 805 material and key consumable suppliers, distributed geographically as follows:

Geographical Distribution of Suppliers



China (including Mainland China, Hong Kong, Macao, and Taiwan)	742
Others	63

Supply Chain Risk Management

The Company manages supply chain risks through regular market analysis and ongoing monitoring, with a focus on maintaining supply stability and resilience. We proactively identify potential risks arising from policy changes, industry trends, and other external factors, including price fluctuations, supply chain disruptions, technological bottlenecks, and capacity constraints. We also place particular emphasis on ESG-related risks within the supply chain, such as environmental impacts, employee rights, information security, and business ethics. To effectively address these risks and ensure the stability and reliability of materials supply, we implement approaches such as supplier diversification, agile procurement, policy monitoring, and digital enablement. These approaches help optimize inventory management, reduce procurement costs, and enhance overall supply chain resilience and market competitiveness.

Zylox-Tonbridge Supply Chain Risk Mitigation Approaches

Diversified Sourcing Strategy

Establish partnerships with suppliers across multiple countries and regions to ensure supply chain diversity and stability.

Agile Procurement Strategy

Mitigate risks arising from external uncertainties by shortening contract durations, optimizing logistics arrangements, and adopting dynamic pricing mechanisms.

Policy Monitoring Strategy

Continuously track global economic developments, industrial policies, and regulatory trends to strengthen risk identification and forward-looking analysis, enabling timely responses to potential policy changes.

Digital Enablement Strategy

Enhance the security and accuracy of information systems to reduce delays and discrepancies in information transmission, and leverage digital tools to improve supply chain transparency and risk forecasting capabilities.

Responsible Procurement

The Company promotes responsible business practices across its supply chain. We have established a *Supplier Code of Conduct* and incorporate requirements relating to environmental protection, production safety, and other key areas into supplier management processes. At the same time, we encourage suppliers to obtain certifications such as ISO 14001 Environmental Management System, ISO 45001 Occupational Health and Safety Management System, and FSC (Forest Stewardship Council) certification, in order to further enhance their ESG management capabilities and performance.

As of the end of the reporting period

Among the Company's material and key consumable suppliers,

209 suppliers were certified under the ISO 9001 Quality Management System

225 suppliers were certified under the ISO 13485 Medical Devices Quality Management System

50 suppliers were certified under the ISO 14001 Environmental Management System

21 suppliers were certified under the ISO 45001 Occupational Health and Safety Management System

The Company upholds the principle of integrity in business operations and fully integrates anti-corruption requirements throughout the entire supply chain management process, striving to build a partnership ecosystem that is honest, compliant, and transparent. We require all suppliers to sign the *Anti-Unfair Competition Commitment* and the *Integrity Commitment Letter*, and provide multiple reporting channels, including telephone hotlines, emails, mailboxes, and website messages, to strengthen oversight of procurement-related misconduct and ensure the effective implementation of integrity requirements.

To reduce the environmental impact of the supply chain, the Company actively promotes green procurement by embedding environmental considerations throughout the lifecycle of packaging procurement and usage. We prioritize the use of recyclable packaging and environmentally friendly materials, and improve packaging design to enhance resource efficiency. In addition, we adopt a scientific supplier selection strategy, giving preference to packaging material suppliers located near our facilities. This approach helps reduce transportation and packaging costs, improve procurement efficiency, and reduce carbon emissions associated with logistics. Furthermore, we optimize transportation arrangements by adopting consolidated shipping arrangements and increasing the use of new energy vehicles, thereby further advancing the low-carbon transition of our supply chain.

United by Talent Growing Together

Zylox-Tonbridge regards talent as a core driver of sustainable development. We respect and protect employees' rights, and have established a high-standard global talent development system to continuously unlock employee creativity, vitality, and potential. At the same time, we foster a corporate culture rooted in diversity, inclusion, equality, and respect, and are committed to building an open, positive, and supportive workplace. We provide employees with a broad platform for growth and development, work alongside talent around the world, and promote shared growth and mutual success between our people and the Company.

Key Issues

Compliance employment
Employee training and development
Prohibition of child labor and forced labor
Employee benefits and care
Occupational health and safety
Community engagement
Inclusive healthcare

SDGs Response

3 GOOD HEALTH AND WELL-BEING
4 QUALITY EDUCATION
5 GENDER EQUALITY
8 DECENT WORK AND ECONOMIC GROWTH
10 REDUCED INEQUALITIES

Chapter Story

Growing with Zylox-Tonbridge to Advance More Human-Centered Medical Innovation

In 2019, Cheng Xin was deeply inspired by the belief that "we practice medicine with conscience and dignity, and the well-being of patients is our greatest aspiration". Driven by a passion for healthcare and a pursuit of technological innovation, she chose to join Tonbridge Medical—a young company with a strong sense of mission.

After joining the Company, Cheng Xin took part in the design and development of several core products. At that time, China's vascular interventional medical device market was still dominated by overseas brands, with high technical barriers and significant R&D challenges. In the face of these difficulties, she and her team rose to the challenge, dedicating themselves to intensive laboratory work. Through iterative design optimization and continuous parameter adjustment, they successfully achieved an optimal balance among catheter flexibility, support, and manufacturing stability. Following clinical application, these products not only provided physicians with more reliable treatment devices, but also expanded access to treatment options for patients. Cheng felt a deep sense of pride, further strengthening her commitment to safeguarding lives.

Over the past seven years at the Company, Cheng has grown from an R&D engineer to an R&D Director. She recognizes that her development has been made possible by the Company's talent development system and management philosophy. Zylox-Tonbridge places strong emphasis on employee growth, supporting new hires through mentorship programs that enable them to quickly develop independence and professional competence. At the same time, the Company actively encourages innovation by establishing comprehensive patent incentive schemes and project-based rewards, providing young R&D professionals with ample space and support. Moreover, the Company upholds a fair and open talent philosophy, offering equal development opportunities to all employees, enabling each individual to fully leverage their expertise, continuously improve in their respective fields, and realize their full potential.

In Cheng's view, Zylox-Tonbridge has not only provided her with a platform to realize her professional expertise, but has also enabled her to align her personal growth with the Company's development goals—transforming passion and expertise into a driving force for advancing life science innovation. Looking ahead, she remains full of aspiration and is committed to moving forward alongside the Company, upholding a spirit of innovation while preserving a human-centered approach. Through professionalism and dedication, she aims to contribute to broader access to high-quality and affordable innovative products and solutions for patients worldwide.

Ensuring Employee Rights

Recruitment Management

Zylox-Tonbridge strictly complies with national labor laws and regulations such as the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China*, and the *Provisions on Prohibiting the Use of Child Labor*, and aligns its employment practices with international standards such as the core conventions of the International Labor Organization (ILO). During the reporting period, we updated the *Human Resources Management Policy*, continuously improved the human resource management system, to safeguard our employees' rights. The Company signs labor contracts with all employees in accordance with the law, and fully respects employees' legitimate rights to freedom of association (including trade union organizations) and collective bargaining. The Company resolutely prohibits illegal employment practices such as child labor and forced labor, and no violations related to illegal employment were identified during the reporting period.

The Company has established policies and documents such as the *Recruitment Management Policy,* the *Employee Probation Management Policy*, and the Job Description to clarify recruitment procedures and standards. We implement a full-process recruitment management model covering demand analysis, structured assessment, background verification, and closed-loop feedback, and leverage the ATS recruitment management system to enable the digital management of recruitment processes, thereby supporting a more systematic and efficient recruitment process. We adhere to the principles of fair and standardized talent recruitment practices, following the recruitment principles of "Role Fit, Competence First, and Cultural Alignment", and we have established scientific and standardized recruitment criteria and selection mechanisms. By introducing standardized assessment tools, we ensure the objectivity and fairness of the recruitment process. Additionally, we regularly assess and optimize our recruitment procedures in response to evolving business needs and market dynamics, continuously improving talent acquisition efficiency and person-role fit.

By the end of the reporting period, the Company had 925 employees, all of whom were full-time. The composition of the employees is distributed as follows:



Male	371	40%
Female	554	60%



Under 30 years old	339	37%
30 to 50 years old	577	62%
Above 50 years old	9	1%



Hangzhou	439	47%
Zhuhai	247	27%
Other regions	239	26%

Remuneration and Performance

The Company continues to improve the compensation and performance management system. We have established the policies, including the *Employee Compensation, Benefits, Leave, and Expense Reimbursement Policy* and the *Performance Management Policy*, to standardize remuneration practices and performance evaluation processes. During the reporting period, we further strengthened the performance appraisal mechanism for key positions to improve its robustness, objectivity and fairness. A multi-dimensional evaluation framework was implemented, focusing on performance contributions, competencies and leadership, with differentiated assessment coefficients applied across employee levels to better align incentives with employee development. At the same time, we carried out the annual salary adjustment for employees, to strengthen the alignment between performance and value creation, and to provide employees with more competitive compensation packages.

Working Hours and Holidays

The Company strictly complies with applicable regulations on working hours and leave management, and ensures employees are entitled to various types of statutory leave, including public holidays, paid annual leave, sick leave, personal leave, and family-related leave such as maternity, paternity and parental leave. Based on job characteristics, we implement a combination of standard and flexible working hours in accordance with the *Attendance Management Policy*, improving work flexibility and efficiency, and supporting employees' career development and work-life balance. During the reporting period, we actively responded to local policies by introducing additional leave benefits, including a parental care leave program for only-child employees to support them in caring for their aging parents. These efforts aim to further strengthen employee well-being and work-life balance.

Equality and Diversity

The Company is committed to fostering a workplace culture of respect, inclusion and equal opportunity, and maintains a zero-tolerance approach to all forms of discrimination, harassment and unfair treatment caused by gender, age, ethnicity, education background, religion, etc. To address misconduct and inappropriate behavior, we have established an anonymous complaint and reporting mechanism for employees, providing them with a safe and confidential channel to raise concerns. This ensures that employee feedback is addressed in a timely manner and resolved appropriately.

Across key areas such as recruitment, compensation and career development, the Company adheres to the principles of fairness, equity and transparency. The Company provides equal development opportunities based on employees' competencies, performance and value contribution, and fosters a diverse and inclusive workplace environment. These efforts support the Company's sustainable development.

By the end of the reporting period, our employee turnover rate was as follows:

Employee structure		Employee turnover rate (%) * in 2025
Total		24.9
By gender	Male	24.6
	Female	25.0
By age	Under 30 years old	29.2
	30 to 50 years old	22.2
	Above 50 years old	10.0
By region	Hangzhou	30.5
	Zhuhai	15.7
	Other regions	21.9

*Employee Turnover Rate Calculation Formula: Employee Turnover Rate = (Number of employees leaving during the reporting period / (Number of employees leaving during the reporting period + Number of employees at the end of the reporting period)) * 100%

Empowering Employee Growth

Strategic Planning for Talent

Zylox-Tonbridge is committed to a people-centered and merit-based approach to talent development. We have established a structured talent strategy focused on leadership, professional capabilities and value creation. The Company implements systematic talent management practices, including talent identification, pipeline development and succession planning, to strengthen workforce capabilities and support sustainable long-term growth. During the reporting period, the Company had 5 employees holding senior or above professional titles and related vocational qualification certificates, 27 employees holding intermediate or above professional titles and related vocational qualification certificates, and 15 employees recognized as high-level talents by the government.

Talent Pipeline

The Company continues to enhance its talent acquisition mechanisms, with a focus on strengthening the talent pipeline for key roles in research and development and clinical functions. By leveraging specialized recruitment channels for R&D and clinical talent, together with resources from universities in China and overseas, the Company has broadened and diversified its talent sourcing network. In addition, the Company actively advances university–enterprise collaboration programs, providing young talent with practical experience and development opportunities, and continuously building a strong pool of specialized professionals to support innovation-driven development.

Talent Standards

The Company has established talent selection standards based on job requirements and competency frameworks, with candidates evaluated on professional capabilities, general competencies, as well as alignment with the Company's values. This helps ensure that the talent selection process remains structured, objective and fair, thereby strengthening talent quality and organizational stability.

Talent Assessment

Through systematic talent review and competency assessment mechanisms, the Company continuously identifies and evaluates key positions and core talent based on capability and performance. This provides a scientific basis for talent development, appointment, and succession planning, while continuously strengthening its talent pipeline to support long-term, stable development.

Talent Development

The Company continues to enhance its talent development system by building a structured talent pipeline that spans different career stages. Through a tiered and differentiated training approach, it supports employees' career progression. Leveraging systematic talent reviews and competency assessments, the Company formulates targeted strategies for talent development, deployment, and retention, and continuously improves its talent pipeline to underpin sustainable growth.

Talent Attraction

We actively expand diversified recruitment channels and adopt a balanced approach to talent acquisition, encompassing international talent, high-caliber professionals, and fresh graduates, to precisely match the needs of positions across different levels and functions. As our global business footprint continues to grow, we proactively recruit professionals with an international perspective, international operational experience, and strong familiarity with local markets. At the same time, through internal selection and diversified development mechanisms, we encourage employees to participate in global expansion, steadily building an international talent pool that supports the Company's global development. In alignment with our differentiated product strategy, the Company continues to strengthen the recruitment and development of key R&D talent. We place particular emphasis on attracting high-level technical professionals with independent R&D capabilities and interdisciplinary expertise, thereby increasing the proportion of highly qualified talent within our R&D team and reinforcing our technological innovation capabilities and R&D efficiency.

International Talent Acquisition

Focusing on the needs of international business development, we continuously expand global recruitment channels to attract professionals with global perspectives and specialized expertise. The Company offers competitive compensation packages and clear career development pathways to support its international expansion.

High-Caliber Talent Acquisition

In line with strategic development priorities, the Company strengthens recruitment for key positions by attracting top-tier technical and managerial talent through multiple channels, including social recruitment and industry referrals, further enhancing professional capabilities and management excellence.

Graduate Recruitment

The Company actively advances campus recruitment programs, leveraging systematic selection processes to attract outstanding fresh graduates. Through a well-established talent development system, we support their career growth and continuously stimulate organizational innovation and vitality.

Summer Social Practice Program for Doctoral Students of Zhejiang University

From August to September 2025, the Company joined hands with the Department of Polymer Science and Engineering of Zhejiang University to launch a summer social practice program for doctoral students. Under the guidance of corporate mentors, 6 doctoral students worked closely with the R&D and manufacturing teams, and conducted research on the application and improvement of biomedical polymer materials in interventional medical devices.

The Company has developed a long-term partnership with Zhejiang University. Through the doctoral summer social practice program, we have effectively promoted the university–enterprise collaboration in the medical device industry. This initiative has created a strong model for talent development and technological innovation, further strengthening the foundation for joint talent cultivation and innovation collaboration between universities and enterprises.

Talent Development

We attach great importance to employee growth and ability development, and continuously build up a multi-level training system. Based on strategic targets and business needs, the Company establishes an annual training plan from the dimensions of professional skills, general qualities and new employee integration, ensuring that the training content is closely aligned with corporate development and employees' career growth. During the reporting period, in accordance with the *New Employee Onboarding Training Management Policy*, the *Company Training Management Policy*, and the *New Employee Onboarding Guide*, we continued to strengthen our employee development system through a broad range of training programs, ongoing improvements to internal development mechanisms, and enhanced learning platforms, thereby improving learning effectiveness and the quality of talent development across the organization. Building on this foundation, we established a three-tier training framework focused on young talent development, professional capability building, and management development. Supported by diversified learning approaches, the framework is designed to meet the development needs of employees at different levels and career stages, and to promote more effective alignment between learning resources and talent development objectives.



Zylox-Tonbridge Human Capital Development Strategy

Zylox-Tonbridge Talent Development System

Young Talent

For new employees, the Company provides onboarding and pre-job training programs that focus on cultural integration and professional conduct. These initiatives help new hires quickly understand the Company's values and code of conduct, enabling a smooth transition into their roles.

Professional Talent

For key employees and professional talents, we focus on improving role-specific capabilities and cross-functional collaboration. Through specialized training programs such as *Management of Project Milestone Achievement*, the Company strengthens professional capabilities and execution efficiency, contributing to both individual growth and improved business performance.

Management Talent

For management personnel, we implement programs such as the *Leadership Navigation Program* and the *Leap Acceleration Camp*. Centered on an "Action Learning" approach, these initiatives focus on cultivating strategic thinking, cross-functional collaboration, and team management capabilities, thereby supporting the development of a high-performing management pipeline.

"Linghang" Leadership Navigation Program: Desert Hike for Collaboration

In October 2025, the Company launched the "Linghang" Leadership Navigation Program, bringing together senior executives and mid-level managers for a 20-kilometer trek across a remote section of the Tengger Desert. Through this experiential learning initiative, which combined physical challenge with teamwork, participants worked together toward a common goal. In the process, they strengthened cross-functional communication, strategic alignment, and collective decision-making, further enhancing the cohesion and execution of the leadership team.

"Leap Forward Accelerator Camp" Training for Core Middle-level Cadres

To strengthen the management talent pipeline and build the leadership backbone for strategy execution, the Company continued to deliver the second phase of its in-person "Leap Forward Accelerator Camp" for mid-level managers and high-potential employees, recording 64 participant attendances in 2025. Built around the Action Learning methodology, the program covered modules such as *Essential Skills for Excellent Managers* and *Value Co-creation*. Through a combination of theoretical learning and practical application, it enhanced the management and cross-functional collaboration capabilities of mid-level managers.

During the reporting period, 836 employees received training, accounting for 90.4% of the total staff. The average training time per employee reached 11.5 hours, and the details of the training are as follows:

Employee Category	Category	Proportion of employees receiving training (%)*	Average training hours per person (hours) **
By gender	Male	43.7	11.1
	Female	56.3	11.7
By employee category	Senior Management	2.0	10.7
	Middle Management	7.7	14.6
	Junior Employees	90.3	11.2

* The proportion of employees receiving training is calculated based on the equation: Proportion of employees receiving training = Number of employees receiving training/Total number of employees * 100%; Proportion of employees receiving training by certain category = Number of employees receiving training under this category/Total number of employees under this category * 100%

** Training hours of employees are calculated based on the equation: Average training hours per employee = Total training hours/Total number of employees; Average training hours per employee by certain category = Total training hours of employees under this category/Total number of employees under this category

The Company strives to improve its employee learning and development mechanisms, encourages all employees to achieve self-improvement through systematic learning, continuously strengthens the continuing education support system based on the *External Training Management Policy*, and promotes the development of a lifelong learning culture. We organized senior executives to participate in external development programs at China Europe International Business School (CEIBS) to enhance their strategic thinking and management capabilities. Meanwhile, we have been building up the incentive mechanism for academic qualification improvement and skill development, providing tuition subsidies and rewards for employees who participate in external courses and qualification examinations. During the reporting period, the Company provided a total of RMB 12,079 in continuing education subsidies and incentives to 13 employees, effectively supporting the improvement of employees' capabilities.

Career Development

We are committed to providing employees with diverse development opportunities, supporting their growth through a dual career track system covering both management and professional pathways. During the reporting period, we further enhanced our job grading and promotion mechanisms, expanding career development opportunities and enabling employees to grow and advance through multiple pathways.

In addition, the Company implements a high-quality internal transfer and job rotation mechanism, guided by employee career development and organizational synergy. This initiative facilitates the rational flow of talent across different business areas, fostering the development of a versatile talent pipeline. During the reporting period, the Company systematically promoted internal talent mobility, with multiple employees transitioning roles through internal transfers. These transitions spanned various categories, including technical, operational, and specialized positions. By providing systematic training and professional coaching, we supported employees in smoothly adapting to their new roles. This approach not only enhances employees' comprehensive skills and cross-functional perspectives but also promotes experience exchange and knowledge sharing across departments. It stimulates innovative thinking from diverse perspectives, further strengthening organizational synergy and fostering a dynamic culture of innovation.

Protecting Health and Safety

Zylox-Tonbridge deeply integrates the safety management principles throughout its operations and is committed to providing employees with a safe and healthy working environment. The Company strictly complies with the laws and regulations of the operating locations, including the *Labor Law of the People's Republic of China*, the *Work Safety Law of the People's Republic of China*, the *Occupational Disease Prevention and Control Law of the People's Republic of China*, and the *Provisions on Occupational Health Management in the Workplace*, among others. We implement internal work safety-related policies such as the Production *Safety Inspection Guidelines* and the *Special Equipment Management Procedure*, and have revised the *Safety Checklist for Hazardous Chemicals Intermediate Warehouse*, the *Safety Warning Sign Management Policy*, the *Special Operators Management Policy*, and the *Special Equipment Management Procedure*, to continuously strengthen safety management systems and their effective implementation. During the reporting period, the Company obtained the ISO 45001 Occupational Health and Safety Management System certification.

We have established a work safety management structure headed by the General Manager, appointed a dedicated Safety Officer, and clarified the safety responsibilities of each department. Besides, to reinforce accountability at all levels, we require all employees to sign the *Work Safety Management Target Responsibility Agreement*. We strictly implement the work safety responsibility system, and practice the concept of zero accident.

Safety Production Organizational Structure Diagram



We adhere to the safety management policy of the "Safety First, Prevention-Oriented, and Comprehensive Management". In compliance with the Safety Target Management Procedure, we set annual safety targets and incorporate them into the performance appraisal system of the EHS department and dedicated personnel. During the reporting period, all the Company's safety targets were fully achieved.

Zylox-Tonbridge Key Safety Targets

0 personal injury accidents

0 incidents resulting in direct economic losses exceeding RMB 50,000

0 fire accidents

0 reported cases of occupational diseases

To ensure the effective implementation of safety responsibilities, the Company decomposes the safety targets to all departments level by level. The person in charge of work safety in each department signs the *Work Safety Management Target Responsibility Agreement*. Through incorporating work safety performance with reward and disciplinary systems, we strengthen the implementation of safety responsibilities. There was no work-related fatality in the past 3 years. During the reporting period, the number of workdays lost due to work-related injuries in production accidents of the Company was 5 days, and the number of workdays lost due to other types of work-related injuries was 27 days.

Work Safety Management

The Company has established a risk management system of "Prevention-oriented, Combination of Prevention and Control", formulated documents including the *Safety Supervision and Hazards Management System*, the *Safety Production Risk Forecasting* and *Early Warning Management System*, and the *Safety Risk Classification Management System*, to regulate management and control of the entire process from risk identification and assessment to rectification and follow-up.

Accurate Identification

In accordance with the *Safety Check List (SCL)*, the *Risk Point Hazard Source Inspection and Control List*, the *Job Hazard Analysis (JHA) Evaluation Form*, and the *Risk Analysis Summary Table*, we systematically identify potential hazard sources and risk-prone processes. Key risk areas, including hazardous chemicals, special equipment, electrical systems, and fire protection facilities, are subject to focused management and control.

Closed-Loop Control

The Company has established an annual risk assessment and dynamic update mechanism to regularly identify safety risks and develop corresponding mitigation measures. A closed-loop process covering identification, notification, rectification, and follow-up has been put in place. The Company also continues to refine its risk control lists, improve emergency response mechanisms, and strengthen employees' risk response capabilities through regular drills.

Strengthened Supervision

The Company adopts a dual control model combining daily inspections and targeted investigations, and conducts ongoing special inspections in key areas such as hazardous chemicals, electrical systems, fire protection, and special equipment. During the reporting period, 77 issues were identified and all were rectified, resulting in a 100% rectification rate. The Company also implemented an incentive mechanism for hazard identification to encourage employees to actively participate in hazard reporting.

Safety Culture Development

The Company deeply embeds safety culture and comprehensively enhances employees' safety awareness and emergency response capabilities through multi-level, diversified training and drills. During the reporting period, the Company systematically carried out three-tier safety education for employees, and held a series of activities including monthly safety meetings, special equipment training, special training on chemical safety, and company-wide lean production training. At the same time, the Company also launched themed training courses on Overall Equipment Effectiveness (OEE), Total Productive Maintenance (TPM) and other topics, to promote the optimization of production processes and reduce safety risks at the source. In addition, we regularly conduct comprehensive fire emergency drills and multi-scenario emergency drills, fully covering key risk scenarios to ensure the efficient applicability of the emergency mechanism. During the reporting period, we organized a total of 4 safety drills and conducted 61 safety training sessions.

The Company strengthens its safety culture by leveraging multiple communication channels, including the official website, WeChat official account, Monthly Magazine, and the public exhibition areas of the industrial park, to promote safety awareness and communicate its safety values, thereby fostering the integration of safety culture into its development.


Fire Extinguisher Use Training


Daily Security Inspections


TPM Knowledge Training

Creating a Positive Workplace Environment

Employee Communication

The Company is committed to fostering a culture of open communication. Building on its continuously improved employee feedback mechanisms, it has established a multi-level, two-way communication system to ensure that employees' views, suggestions, and concerns are heard and addressed in a timely manner. Through the regular communication mechanism and hierarchical processing procedures, the Company has effectively promoted mutual understanding and trust between employees and the management, and created an open, transparent and inclusive working environment. During the reporting period, the Company continuously collects and processes employee feedback daily, implementing optimization and improvement measures item by item in response to the reasonable suggestions put forward by employees on the catering environment, staff dormitories, team building activities, afternoon tea benefits and other aspects. In addition, we conduct annual employee satisfaction and engagement surveys. Questionnaires are designed based on the Gallup Q12 Employee Engagement framework to systematically gauge employees' overall evaluation of the workplace, team atmosphere, and career development. During the reporting period, the Company conducted the 2025 Zylox-Tonbridge Group Organizational Health and Employee Engagement Survey across all employees, receiving a total of 827 valid responses. The overall employee satisfaction rate reached 88.35%, providing valuable insights for continuously improving employee experience and management systems.

Communication Channels for Our Employees

- Employee Meeting
- Internal Communication Platform
- Employee Satisfaction Survey
- General Manager Mailbox
- Communication and Interview on Performance
- Various Interviews and Symposiums

Employee Benefits

The Company cares about employees' physical and mental well-being, and continuously enhances its employee benefits framework. To strengthen employee support and care, we have established and implemented the *Benefits Distribution Management Policy* and the *Company Product Usage Welfare Policy*. These policies provide meaningful support in areas including health and well-being, daily living assistance, and employee care. During the reporting period, the Company introduced a new *Welfare Policy*, further clarifying benefit items, eligibility, and distribution criteria to ensure the fair and consistent implementation of the policy.

We provide employees with a broad range of benefits and care programs, including annual health check-ups, housing subsidies, long-service awards, festival benefits, company retreats, and wellness and leisure facilities. In 2025, the Company further strengthened employee care by increasing the budget for team-building activities and providing meal allowances and transportation subsidies for night-shift employees. It also refined its *Rental Subsidy Management Regulations* in alignment with local talent housing policies, and introduced the "Boundless Care" commercial supplementary medical insurance program to offer employees more comprehensive health and livelihood protection.

"Empowering Women, Radiating Brilliance" – International Women's Day

To celebrate International Women's Day 2025, Zylox-Tonbridge organized a themed event centered on "Diversity, Confidence, and Shared Growth" with over 200 female employees participating. The event featured interactive activities such as a themed luncheon, a creative food-making workshop, and a prize draw, creating a warm and engaging atmosphere. The program also included the recognition of outstanding female employees, a sharing session, and collaborative activities, highlighting the creativity and teamwork of participants. The event strengthened employee engagement and organizational cohesion, reflecting the Company's commitment to supporting the growth and value of female employees.

Employee Activities

In order to foster a positive and dynamic work environment, the Company consistently organizes a diverse range of employee activities, which promote team integration and enhance employees' sense of belonging and cohesion. In 2025, the Company organized a series of activities, including the Zylox-Tonbridge 13th Anniversary Employee Sports Day, the Zylox-Tonbridge 2025 Mid-Autumn Festival Special Activity, and the Dragon Boat Festival themed event. These diverse cultural activities have consistently deepened corporate cultural identity, stimulated employee enthusiasm and creativity, and provided strong support for building a warm and fulfilling workplace environment at the Company.

"A Decade of Journey, Unveiling a New Chapter" –Tonbridge Medical Honors Employee Contributions

In March 2026, Tonbridge Medical held its 10th Anniversary Celebration and Employee Recognition Ceremony. At the event, the Company's management reviewed the journey from initial exploration to steady growth, expressing gratitude for the dedication and efforts of all employees, and outlined the future development vision.

On the day of the ceremony, Tonbridge Medical also held its annual awards and long-service recognition event, recognizing exemplary individuals, outstanding teams, and role models for collaboration, and further fostering a culture of dedication and teamwork. Additionally, the Company presented "Service Contribution Awards" and commemorative gifts to employees who have accompanied the Company through years of development, acknowledging their enduring support—"from first encounters to deep dedication, from walking together to sharing a common purpose".

Through employee recognition and incentive programs, the Company continues to foster an organizational culture that respects contributions and encourages dedication, enhancing employees' sense of belonging and team cohesion. This provides a solid talent foundation for the Company's long-term and stable growth.

Building a Better Community Together

Public Charity

Zylox-Tonbridge leverages its professional expertise and resources to organize initiatives such as charitable medical seminars, contributing to the development of a multi-level medical support system and promoting shared social value. By utilizing the" Zylox-Tonbridge Public Welfare and Charity Special ", we provide support and assistance to patients facing financial difficulties in accessing medical treatment, consistently extending care to more lives. As of the end of the reporting period, the fund has raised a cumulative total of RMB 4.50 million, benefiting over 280 patients. Additionally, the Company actively participates in local public welfare initiatives and community development. During the reporting period, it carried out a range of charitable and community activities, including voluntary blood donation drives and charity auctions, bringing together collective efforts to support communities through diverse forms of engagement.

"Winter Sunshine, Celebrating the New Year Together" — Yuhang Charity Union Event

In January 2025, the Company participated in the public welfare activity "Winter Sunshine, Celebrating the New Year Together", organized by the Yuhang Charity Union in Hangzhou. The initiative involved donating 100 insulated cups as care packages to disadvantaged families, sanitation workers, delivery riders, and couriers within the district, conveying warmth and empathy while promoting a spirit of goodwill and mutual support in the community.

Public Health Education

Leveraging its strengths in medical technology, the Company has deepened its collaboration with the Zhejiang Provincial Federation for Science Popularization and the Zhejiang Shen Kuo Science Kommunikation Foundation. We have donated RMB 500,000 to establish the "Healthcare Science Popularization Special Fund", aimed at advancing the dissemination of public healthcare knowledge. At the same time, the "Corporate-Community Joint Health Education Initiative" was officially launched and welcomed its first community engagement cohort, marking the transition of the Company's health education efforts into a regularized and systematic phase.

"Embracing Health · Approaching Vascular Wellness" Corporate Open Day and Silver Age Public Welfare Science Popularization Research Activity

In November 2025, the Company, together with the Future Envoys outreach team under the Zhejiang Federation for Science Popularization, hosted the "Embracing Health · Approaching Vascular Wellness" Corporate Open Day. Elderly residents from Mengchuang Community in Cangqian Subdistrict were invited to visit Zylox-Tonbridge Industrial Park. A health education session was also held to share knowledge on the prevention and management of vascular diseases, as well as key concepts in interventional therapies. The activity helped enhance health awareness among the elderly population and strengthened engagement between the Company and the local community.



Green Operations Protecting the Future Together

Zylox-Tonbridge actively responds to the global transition toward a greener, low-carbon economy by continuously strengthening its climate governance capabilities. We are committed to advancing cleaner and more environmentally responsible operations, developing eco-friendly manufacturing sites, and contributing to global sustainable development. Through these efforts, we aim to support a more balanced and enduring relationship between business, society, and the natural environment.

Key Topics[1]

Climate change response
Energy management
Discharge management
Water use
Packaging material management

SDGs Response

7 AFFORDABLE AND CLEAN ENERGY
13 CLIMATE ACTION
17 PARTNERSHIPS FOR THE GOALS

[1] In 2025, due to increased product sales and the expansion of production areas, environmental indicators such as energy consumption, greenhouse gas emissions, water use, packaging material consumption, and emissions rose compared with 2024.

Chapter Story

Zylox-Tonbridge Opens Innovation Park, Building a Green and Low-Carbon Manufacturing Site

The health and well-being of humanity are closely intertwined with the environment and ecosystems on which we depend. Zylox-Tonbridge consistently upholds the philosophy of harmonious coexistence between humanity and nature, and, acting on the national "Dual Carbon" strategy, is dedicated to creating a green, efficient, and intelligent modern manufacturing park. The Zylox-Tonbridge Innovation Park, located in Lin'an District, Hangzhou, Zhejiang Province, was officially completed in 2025. The manufacturing site is designed with a strong focus on resource efficiency, reduced environmental impact, and low-carbon, intelligent operations. Through these principles, it advances green development, and strengthens the Company's foundation for high-quality, sustainable growth.

Energy Efficiency and Carbon Reduction

Energy consumption across buildings and operations is reduced through optimized daylight access, high-performance thermal insulation systems, and the integration of clean energy, intelligent energy monitoring, and energy-efficient equipment.

Sustainable Materials

We have adopted lightweight, high-strength construction materials, including autoclaved aerated concrete (AAC) blocks and thermal-break aluminum alloys. This approach reduces reliance on more energy-intensive materials and enhances the overall environmental performance of our buildings.

Resource Efficiency

Through land-efficient design, we improve land-use efficiency, while the use of rainwater harvesting, water-saving fixtures, and ecological landscaping supports the recycling and efficient use of water resources.

Responding to Climate Change

Climate change is a major global challenge and an important consideration for corporate sustainability. Zylox-Tonbridge integrates climate action into its operations and management practices. By strengthening its governance framework, enhancing risk management, and advancing low-carbon practices, the Company continuously improves its climate resilience.

Governance

The Board of Directors places great importance on the management of climate-related risks and opportunities, actively fulfilling its responsibilities for climate governance. It oversees the management of climate-related issues and ensures that climate considerations are incorporated into the Company's strategic planning, major operational decisions, risk management processes, and relevant policy development. To strengthen the Board's expertise, we regularly provide updates on the latest climate policies and industry trends, supporting the Board's understanding of the potential impacts of climate change on the Company's business and operations. We have deeply integrated climate mitigation and adaptation actions into core business activities. We have deeply integrated climate change mitigation and adaptation actions into core business processes, including manufacturing. Management teams across business units are responsible for overseeing implementation, while climate-related performance indicators, including energy consumption, are incorporated into the remuneration and performance assessment framework to help ensure the effective implementation of climate initiatives.

Strategy

The Company fully recognizes the significant impact of climate-related risks and opportunities on the socio-economic environment and business operations. We closely monitor the latest developments in climate change and global climate governance. Through industry research and internal discussions, we identify and assess climate-related risks and opportunities, and apply scenario analysis to evaluate their potential impacts and the Company's climate resilience. Based on these assessments, we continuously refine our risk management measures and response strategies to strengthen our capacity to adapt to climate change.

Assessment of Climate Risks and Opportunities

Given the long-term and systemic nature of climate change, we adopt a medium-term time horizon and conduct periodic identification and reassessment of climate-related risks and opportunities, taking into account changes in external sustainability trends and internal business factors. This ensures that our analysis remains aligned with the Company's operating realities and evolving external trends. In 2025, considering the Company's current operations, business plans, and industry trends, we reviewed and evaluated the identified climate-related risks and opportunities. The results indicate that 4 climate-related risks and 2 climate-related opportunities remain applicable to the Company, with low to moderate levels of impact. During the reporting period, climate-related risks and opportunities did not have a material impact on the Company's financial position, financial performance, or cash flows, and are not expected to result in significant adjustments to the carrying amounts of assets and liabilities in the next reporting period.

Risk/ Opportunity category		Risk/ Opportunity event	Level of impact			Impact on value chain
			Short-term	Medium-term	Long-term	
Physical risk	Acute	Extreme weather	Low	Medium	Low	• Production and manufacturing • Warehousing and logistics
	Chronic	Rising average temperature	Low	Medium	Medium	• Production and manufacturing • Warehousing and logistics
Transition risk	Market	Resource price volatility	Low	Medium	Low	• Procurement • Production and manufacturing • Warehousing and logistics
	Technology	Cost of transitioning to low-carbon operations	Low	Medium	Low	• Procurement • Production and manufacturing
Opportunity	Resource	Resource substitution and diversification	Low	Medium	Medium	• Procurement • Production and manufacturing • Warehousing and logistics
	Products and services	Ongoing research and development of innovative medical devices or services	Low	Medium	Medium	• Production and manufacturing • Marketing

● Low risk ■ Medium risk ▲ High risk ● Low opportunity ■ Medium opportunity ▲ High opportunity

Note: Taking into account the Company's business planning, as well as national or regional climate-related policies, we define the short-, medium-, and long-term time span as 0-3 years, 3-10 years, and more than 10 years, respectively.

Scenario Analysis

We conduct a comprehensive analysis of the impacts of climate-related risks and opportunities on the Company's operations and value chain by referencing the publicly available IPCC climate scenarios, including the low emission scenario model (RCP 2.6) and high emission scenario model (RCP 8.5) of IPCC.

Climate scenario	Low emission scenario RCP 2.6 (IPCC)	High emission scenario RCP 8.5 (IPCC)
Description	Assuming strong global mitigation measures are adopted, greenhouse gas (GHG) concentrations stabilize at low levels, thereby achieving the target of limiting global temperature rise to 1.5° C specified in the Paris Agreement. GHG emissions peaked around 2020 and declined rapidly thereafter, to reach net negative emissions by 2100.	Assuming no effective climate policies are adopted globally, GHG emissions continue to grow rapidly, leading to severe climate change impacts. GHG emissions continue to rise and will not peak even by 2100, with the global temperature rise exceeding 4° C.

Risk category		Risk description and potential financial impacts	Management initiatives
Physical risk	Acute	• **Extreme weather:** Increased frequency and severity of extreme weather such as typhoons and floods may cause damage to the Company's operating infrastructure assets and disruptions to the supply chain.	• Establish prevention, monitoring and early warning mechanisms to address extreme weather risks, and establish internal policies including the *Safety Measures Against Extreme Weather*, the *Control Procedures for the Identification and Evaluation of Environmental Factors,* and the *Extreme Weather Emergency Response Plan*. Moreover, carry out regular emergency drills to enhance response capabilities for extreme weather events. • Increase inventory levels based on production needs and establish a diversified supplier network to ensure production continuity.
	Chronic	• **Rising average temperature:** Rising average temperature due to global warming may bring challenges to our production and operations. For instance, the energy consumption of temperature control in the production process may increase, boosting the expenditure on energy consumption.	• Strengthen energy management, analyze energy consumption trends, and reduce energy consumption for refrigeration in production and daily operations through intelligent temperature control of refrigeration facilities.
Transition risk	Market	• **Resource price volatility:** Climate change will lead to an increase in the price of key resources such as energy, water, raw materials and packaging materials, resulting in higher production costs.	• Reduce dependence on a single source of supply and promote the use of alternative materials.
	Technology	• **Cost of transitioning to low-carbon operations:** The Company may need to make significant initial capital investment to undertake low-carbon operational transitions, such as adopting low-carbon technologies and materials, renewable energy, retrofitting processes, and introducing energy-efficient and low-carbon equipment.	• Actively seek opportunities to improve the efficiency of existing equipment while expanding the use of clean energy.

Opportunity category	Description and impact of opportunities	Management initiatives
Resource substitution and diversification	• Reduce operating cost by increasing the stability and reliability of the supply chain with diversified resource supply.	• Actively explore innovative solutions for cleaner energy and alternative materials, and work with value chain partners to advance resource substitution and diversification practices.
Ongoing research and development of innovative medical devices or services	• With the increasing concern for sustainability and growing market demand for low-carbon and environmentally friendly medical products, the Company can develop products with environmental protection advantages. By this means, the Company can establish differentiation in the market and enhance market competitiveness.	• Increase R&D investment in low-carbon and environmentally friendly products, and optimize operational efficiency and manufacturing processes, so as to reduce energy consumption in the production process, and enhance green competitiveness of products.

Under the low-emission climate scenario (RCP 2.6)

Achieving the goal of limiting global temperature rise to within 1.5° C will require rapid and large-scale emissions reductions worldwide. Governments and regulators may introduce more stringent policies and regulations, such as restrictions on fossil fuels and mandatory renewable energy targets. At the same time, market expectations for low-carbon technologies and green products will increase significantly, raising the likelihood of transition risks for the Company. In this scenario, we will need to increase investments in various energy-saving initiatives and adjust our energy mix, which may lead to higher operating costs. In addition, suppliers may raise raw material prices to meet compliance requirements, resulting in increased procurement costs.

Under the high-emission climate scenario (RCP 8.5)

In the absence of more effective government and market interventions to reduce greenhouse gas emissions, extreme weather events are expected to become more frequent and severe, and average temperatures will continue to rise. As a result, the Company will face significantly higher physical climate risks compared to transition risks. In this scenario, the increased frequency of extreme weather events may heighten the risk of production disruptions, damage to operational infrastructure, and supply chain interruptions, potentially leading to a decline in the Company's net assets and operating revenue. Furthermore, rising temperatures will increase demand for cooling equipment such as air conditioning and refrigeration, thereby driving up energy consumption and production costs.

Note: During the reporting period, quantitative assessment of climate-related risks and opportunities was not conducted, as the data accumulation and technical capabilities required for such analysis are still under development. In the future, we will carry out quantitative analyses of significant risks in a timely manner, based on their materiality and significance.



In 2025, the results of the climate scenario analysis remain applicable to the Company's management practices. We have continued to enhance our climate resilience and operational robustness through strengthened measures. In particular, the Company regards energy management as a key pathway to addressing climate change challenges. We strictly comply with relevant laws and regulations, including the *Energy Conservation Law of the People's Republic of China*, and continuously enhance our energy management system. Through initiatives such as promoting the use of clean energy, optimizing system equipment, strengthening daily monitoring, and conducting energy-saving awareness programs, we aim to enhance energy efficiency and reduce carbon emissions across our operations.

Zylox-Tonbridge's Green Electricity Certificate Transaction Vouchers

Use of Clean Energy

We actively promote renewable energy initiatives, including photovoltaic power generation and the purchase of renewable energy green electricity certificates, to continuously increase the proportion of green energy consumption. During the reporting period, the Company generated 473.27 MWh of electricity from photovoltaic systems, with renewable energy accounting for 5.74% of total energy consumption. In addition, we purchased 1,000 green electricity certificates, equivalent to reducing 570.3 tons of carbon dioxide emissions.

Optimization of System Equipment

We optimize system equipment by developing shared systems for purified water production, air conditioning, and process gas supply, enabling centralized resource allocation and more efficient use of resources.

Strengthening Daily Monitoring

We have established routine inspection mechanisms for office areas. Lighting systems and air conditioning units are equipped with automatic power-off functions during non-working hours, along with electronic reminders to switch off equipment, thereby reducing unnecessary electricity consumption.

Energy Conservation Awareness Initiatives

We have developed green office guidelines and displayed posters and signage promoting energy conservation and carbon reduction in both office and production areas to raise employees' awareness of energy conservation.

Risk Management

To effectively address an increasingly complex and evolving climate environment, the Company integrates the identification, assessment, prioritization, and monitoring of climate-related risks into its Company-wide risk management framework and processes. This ensures that climate-related risks are identified and evaluated with the same importance as operational, financial, compliance, and other key risks. At the same time, we develop scientifically informed climate risk management measures tailored to our business realities, continuously enhancing the Company's climate resilience and response capabilities, and supporting sustainable development.

Response to Typhoon Matmo

The Company consistently prioritizes workplace safety, employee health, and the protection of assets, continuously improving its emergency management system for extreme weather and enhancing disaster prevention, mitigation, and risk response capabilities. In October 2025, in response to Typhoon Matmo, the Company established an emergency typhoon response task force, strengthened coordinated response mechanisms, and implemented strict on-duty staffing arrangements to ensure all precautionary measures were effectively executed. Comprehensive safety inspections were conducted, temporary power shutdowns were implemented in office areas, and key infrastructure—including doors and windows, rooftop facilities, underground garages, and campus landscaping—was reinforced to reduce the typhoon's impact on personnel safety, equipment, and property. The Company also took timely work and production suspension measures as appropriate, ensured the availability of emergency supplies, and strengthened employee awareness of typhoon and flood preparedness. Following the typhoon, comprehensive inspections, repairs, and corrective actions were promptly carried out, further enhancing operational resilience.



Metrics and Targets

In 2025, our Hangzhou base set an energy consumption target to reduce electricity use per unit of revenue by 1% compared with 2024. To achieve this, we implemented refined management measures, including enhanced control of air conditioning operations, optimization of outdoor unit heat dissipation, precise adjustment of chiller parameters, and strict control of cleanroom exhaust. These initiatives helped steadily reduce electricity consumption and ensure the annual energy target was met. At the same time, we monitor and analyze energy use and carbon emissions data. Based on operational realities and business development plans, we intend to establish more scientifically grounded and feasible energy efficiency and carbon emission management targets in future reporting periods. During the reporting period, as climate-related risks and opportunities had no material impact on the Company[1], no internal carbon pricing mechanism was implemented.

During the reporting period, the Company's energy use and greenhouse gas emissions were as follows:

Category	2025	2024	2023
Energy consumption[2]			
Direct energy consumption	2,066.46	1,439.71	1,389.01
Including: Gasoline (MWh))	108.30	53.46	49.39
Natural gas (MWh)	1,484.89	1,100.69	1,339.62
Self-Generated Photovoltaic Power (MWh)	473.27	285.56	/
Indirect energy consumption	6,183.49	4,556.73	5,281.12
Including: Purchased electricity (MWh)	6,183.49	4,556.73	5,281.12
Total energy consumption (MWh)	8,249.95	5,996.44	6,670.13
Energy consumption intensity(MWh/RMB million revenue)	7.80	7.66	13.64
Greenhouse gas emissions[3]			
Total greenhouse gas emissions (tCO_2e)	3,849.82	2,831.84	3,291.74
Including: Scope 1 emissions (tCO_2e)	323.37	233.14	279.92
Scope 2 emissions (tCO_2e)	3,526.45	2,598.70	3,011.82
Greenhouse gas emission intensity(tCO2e/RMB million revenue)	3.64	3.62	6.24

Note: 1. Material Assets and Climate-Related Impacts: The Company does not hold material assets that are highly sensitive to climate-related transition or physical risks. Climate-related risks and opportunities have had no significant impact on the Company. During the reporting period, no assets or business activities were identified that required separate quantitative disclosure due to susceptibility to climate-related risks or opportunities. No separate capital expenditure, financing, or investment arrangements were made for climate-related matters, and no cross-industry indicators are disclosed.

2. Energy Consumption: Energy consumption calculations refer to the national standard GB/T 2589-2020 General Rules for Comprehensive Energy Consumption Calculation, issued by the State Administration for Market Regulation and the Standardization Administration of China. In 2025, we optimized the statistical method for direct energy consumption by including self-generated photovoltaic electricity, and updated the 2024 energy consumption data accordingly.

3. Greenhouse Gas Emissions: Calculation methods and emission factors follow the GHG Protocol, the National Development and Reform Commission's Guidelines for Greenhouse Gas Accounting and Reporting for Other Industrial Enterprises (trial), and the Ministry of Ecology and Environment's notice on managing GHG reporting for power generation enterprises (2023–2025). Due to the complexity and limited availability of upstream and downstream data for Scope 3 emissions, the accounting basis is not yet fully established; therefore, Scope 3 greenhouse gas emissions are not disclosed for this reporting period. In the future, once data availability and accounting capabilities are sufficiently developed, we will initiate Scope 3 emissions accounting and disclosure.

Advancing Green Operations

Environmental Management

The Company actively fulfills its environmental responsibilities and strictly complies with laws and regulations, including the *Environmental Protection Law of the People's Republic of China*, the *Water Pollution Prevention and Control Law, the Air Pollution Prevention and Control Law*, and the *Law on Prevention and Control of Environmental Pollution by Solid Waste*. We have established an environmental management structure led by business line General Managers and the Vice President of Operations. At the Company level, dedicated environmental managers are appointed, and at the departmental level, environmental officers are designated, forming a top-down management system to ensure effective implementation of environmental policies. During the reporting period, the Company obtained ISO 14001 Environmental Management System certification.

We have developed and implemented policies including the *Wastewater Management Procedure*, the *Solid Waste Pollution Control Procedure,* the *Toxic and Hazardous Chemical Control Procedure*, the *Hazardous Materials Storage Management Regulations*, and the *Facilities and Workplace Environment Control Procedure*. We establish management targets for wastewater, air emissions, and solid waste, and continuously improve related pollution prevention and control measures. While ensuring compliance with national and local standards, we strive to minimize the impact of our operations on air, water, soil, and the surrounding environment.

Exhaust Gas Management

- **Air Emissions Treatment:** High-efficiency filters are installed at the exhaust end of air handling systems in cleanrooms to control organic pollutants in production exhaust. Activated carbon adsorption devices are installed at the exhaust outlets of spraying equipment to reduce the concentration of exhaust from spraying processes and minimize air pollutant emissions. During the reporting period, we upgraded exhaust ducts to further improve the efficiency of exhaust collection and treatment.
- **Process Optimization:** We optimize sterilization workflows by implementing centralized sterilization by product category, thereby reducing the operating frequency of sterilization equipment and minimizing the generation of process-related exhaust emissions at the source.

Wastewater Management

- **Neutralization Treatment:** Production wastewater is uniformly neutralized before being discharged through dedicated outlets into the municipal sewage network for centralized treatment at local wastewater treatment plants, ensuring compliance with relevant discharge standards.
- **Pipeline Inspection:** Drainage pipelines are regularly inspected and repaired promptly to prevent wastewater leakage or external discharge that could cause environmental pollution.
- **Process Optimization:** We implement centralized sterilization for similar products, optimizing water use and discharge processes to reduce wastewater from sterilization. During the reporting period, process optimization projects were actively advanced, with key production stages improved through technical upgrades to minimize wastewater discharge.
- **System Upgrades:** The purified water system was optimized to reduce wastewater generated during disinfection, thereby lowering water resource consumption and alleviating wastewater discharge pressure at the source.

Waste Management

- **Hazardous Waste:** Hazardous waste, including used alcohol, organic solvent waste, mixed inorganic waste, waste mineral oil, and spent activated carbon, is collected and managed centrally and regularly handed over to qualified third-party processors for treatment.
- **Non-Hazardous Waste:** Non-hazardous waste such as office paper and cardboard is classified, collected, and recycled to maximize resource efficiency and minimize waste generation.
- **Domestic Waste:** Domestic waste is sorted according to classification requirements, transported by professional service providers, and cleared daily to ensure proper disposal.

The major sources of our exhaust emissions are welding fumes generated during production process and laboratory exhaust, which are treated through activated carbon adsorption systems. The resulting emissions are minimal and have no material impact on the surrounding environment; therefore, the exhaust emission data are not disclosed in this report. During the reporting period, our performance on pollutant-related indicators was as follows:

Category	2025	2024	2023
Wastewater discharge			
Wastewater discharge (ton)	35,082.59	29,559.54	27,858.72
Including: COD discharge (ton)	2.60	1.82	1.71
Ammonia nitrogen discharge (ton)	0.31	0.25	0.23
Waste generation			
Total hazardous waste (ton)	12.02	5.23	2.50
Hazardous waste intensity (ton/ RMB million revenue)	0.011	0.007	0.005
Total non-hazardous waste (ton)	28.95	17.60	13.94
Non-hazardous waste intensity (ton/ RMB million revenue)	0.03	0.02	0.03

Resource Utilization

Water Resource Management

The Company places great emphasis on water resource management and strictly complies with laws and regulations, including the *Water Law of the People's Republic of China*, continuously optimizing water use practices. Our primary water source is municipal supply, with water consumption mainly associated with process water used in R&D and production, cleaning activities, and domestic use. During the reporting period, the Company did not encounter any issues in obtaining water resources. To improve water efficiency, our Hangzhou base set a 2025 target to reduce water consumption per RMB 100,000 of revenue by 0.5 tons from 2024 levels. A series of water management measures have been implemented to support the achievement of this target. Additionally, based on management needs and business planning, we will establish scientifically grounded water efficiency targets in future reporting periods to further improve water use efficiency.

Recycling and Reuse

A cooling water recirculation system is used to recover and reuse cooling water from the production process, significantly reducing freshwater consumption and improving water-use efficiency.

Daily Management

Water use in living and office areas is optimized by adjusting faucet flow rates, reducing unnecessary domestic water consumption.

Awareness and Education

Water conservation signage is displayed in public areas, such as restrooms and tea rooms, to encourage employees to adopt water-saving habits.

During the reporting period, our consumption of water resources was as follows:

Category	2025	2024	2023
Water consumption			
Tap water consumption (ton)	38,980.65	32,843.94	30,954.13
Tap water consumption intensity (ton/ RMB million revenue)	36.86	41.97	58.65

Packaging Material Management

The Company practices responsible consumption and production, continuously improving the environmental performance of packaging. We strictly follow the 3R principle—Reduce, Reuse, and Recycle, and promote greener, lighter, and more resource-efficient packaging through design improvements, recycling, and proper disposal, thereby reducing the environmental impact of packaging materials. During the reporting period, we reduced packaging material usage by a total of 10.32 tons.

Design Improvement

Packaging design and dimensions were optimized to avoid over-packaging. During the reporting period, certificates of conformity and sterilization indicators were printed directly on paper-plastic pouches, reducing the use of packaging materials.

Reuse

Undamaged and reusable cardboard boxes are recycled within the Company, reducing the demand for new boxes.

Recycling and Disposal

Damaged cardboard boxes are collected and processed by third-party recyclers to ensure that discarded packaging materials are properly managed.

During the reporting period, the Company's packaging material consumption was as follows:

Category	2025	2024	2023
Packaging materials consumption			
Total consumption of packaging materials (ton)	92.13	50.25	15.50
Consumption intensity of packaging materials (ton/ RMB million revenue)	0.09	0.06	0.03

Responsible Governance Acting with Integrity and Diligence

Zylox-Tonbridge is dedicated to becoming a multinational medical technology company that originates from China and serves the global market. We are strengthening our governance and compliance management system across the global business chain to ensure strict compliance with the laws, regulations, and regulatory requirements across all regions where we operate. This commitment ensures business compliance and effective risk management. Throughout our globalization journey, we uphold high standards of business ethics and responsible practices, driving quality growth while creating shared social value.

Key Topics

Business ethics
Anti-corruption
Information security and privacy protection
Intellectual property management

SDGs Response

Strengthening Corporate Governance

Zylox-Tonbridge strictly complies with relevant laws and regulations such as the *Company Law of the People's Republic of China*, the *Securities Law of the People's Republic of China*, and the *Code of Corporate Governance for Listed Companies* and other laws and regulations. We have established and continuously refined the *Articles of Association* and various corporate management policies. Through a robust oversight and management mechanism, the Company consistently enhances governance transparency and operational efficiency to create long-term sustainable value for all stakeholders.

Governance Structure

The Company's governance structure consists of the General Meeting of Shareholders, the Board of Directors, and the Supervisory Committee. The General Meeting of Shareholders serves as the highest authority, under which the Board of Directors acts as the decision-making body and the Supervisory Committee functions as the supervisory body. Both the Board of Directors and the Supervisory Committee are appointed by the General Meeting of Shareholders. The Board of Directors appoints the senior management team as the executive body. The Board of Directors has established three specialized committees—the Audit Committee, the Remuneration Committee, and the Nomination Committee—to support rigorous and professional decision-making. During the reporting period, the Company held 2 General Meetings of Shareholders, 5 Board meetings, and 3 Board of Supervisors meetings.

Zylox-Tonbridge Governance Structure



Board Diversity

We prioritize Board diversity and are committed to maintaining a meaningful level of diversity in terms of gender, ethnicity, professional background, industry experience, and cultural perspectives, to enhance the Board's strategic insight and decision-making capabilities. In the director nomination and appointment process, we evaluate candidates across strategic management, quality control, financial and risk management, expertise in specialized fields, and international experience, bringing diverse perspectives to our high-level decision-making.

As of the end of the reporting period

the Board of Directors consists of **8** directors

including **3** independent directors

and **1** female director

Adhering to Compliance Operation

Risk Control

Risk Management

We have established a systematic risk management framework, integrating risk management into corporate governance and operational decision-making. We continuously enhance our capabilities in risk identification, assessment, and response to ensure business resilience and sustainable growth. The Company has formulated and implemented the Risk Management System, defining risk management responsibilities for the Board, management, and all functional departments. This framework establishes a comprehensive closed-loop risk management process encompassing Identification, Assessment, Response, Monitoring, and Feedback. It covers both external environmental risks—such as economic and market fluctuations, policy and regulatory changes, sustainability and climate challenges, as well as geopolitical and international trade uncertainties—and internal management risks, including information security, operational and supply chain vulnerabilities, as well as R&D and product quality concerns. In addition, the Board and CEO receive semiannual risk management reports to oversee the effective implementation of risk mitigation measures.

Risk Management Mechanism

Risk Identification and Assessment

All departments regularly gather information on risks related to business operations, policies, markets, operations, sustainability, and climate change. They identify, categorize, and quantitatively assess key risks that may impact the Company's strategic objectives.



Risk Response

Based on the nature of different risks, the Company adopts appropriate response strategies, including avoidance, mitigation, acceptance, and transfer, and implements corresponding control measures in a timely and effective manner.

Monitoring and Improvement

We continuously track changes in significant risks and the effectiveness of controls, regularly review the suitability of the risk management system, and dynamically optimize prevention mechanisms in line with business development.

Capacity Building

Through risk management training and awareness-building activities, the Company enhances employees' risk awareness and response capabilities, and strengthens the integration of risk prevention and control into daily operations.

Audit Supervision

The Company places high importance on the establishment of internal audit and compliance supervision systems, continuously strengthening the two-way combination between internal review and external evaluation. During the reporting period, we conducted annual routine audits and ad hoc inspections focusing on OA system workflows, with particular emphasis on four major dimensions: expense reimbursement compliance, marketing meeting management, procurement processes, and the implementation of anti-bribery clauses. Throughout the year, two systematic audits were completed, with no violations identified. Overall processes were found to be operating in a standardized and effective manner. Meanwhile, the Company conducted annual evaluation audits for conference service providers, rigorously reviewing the compliance of evaluation procedures and the participation of multiple departments to ensure the process was transparent, fair, and efficient. Currently, the related results are under assessment.



Anti-Corruption and Business Ethics

Zylox-Tonbridge consistently upholds the principles of lawful governance and integrity in business. We strictly comply with relevant laws and regulations, including the *Criminal Law of the People's Republic of China, the Anti-Money Laundering Law of the People's Republic of China*, and the *Anti-Unfair Competition Law of the People's Republic of China*. Furthermore, we comply with applicable laws, regulations, and international standards—such as the *United Nations Convention against Corruption*—pertaining to fair competition, anti-bribery, and anti-corruption in all jurisdictions where we operate. We continuously enhance our anti-corruption and business ethics management systems to ensure the compliant and stable development of the enterprise. The Company has established the *Anti-Corruption and Anti-Bribery Policy*, the *Anti-Fraud Management Policy*, the *Anti-Money Laundering Measures and Policy*, and the *Trade Secret Protection Management Policy*, continuously refining our anti-corruption and business ethics management system. During the reporting period, the Company systematically revised the *Zylox-Tonbridge Supplier Code of Conduct* and the *Zylox-Tonbridge Anti-Bribery* and *Anti-Corruption Policy*, creating bilingual versions in Chinese and English, which were officially published on the Company's official website. This aims to strengthen compliance guidance for employees, suppliers, and partners, further enhancing the Company's integrity and compliance management capabilities in global operations.

Integrity Management

To prevent and address corruption and bribery, we maintain dual integrity controls for both internal employees and external business partners. Through our *Employee Handbook*, we have established a clear code of business conduct and ethics applicable to all employees. This code prohibits practices such as fraud, improper profit-seeking, and unauthorized disclosure of commercial information. Upon joining, employees sign the *Integrity and Self-Discipline Commitment* and the *Non-Disclosure Agreement*, while all senior management personnel complete the *Conflict of Interest Questionnaire*. During the reporting period, the signing rates for both the *Integrity and Self-Discipline Commitment Letter and the Compliance Commitment Letter* reached 100%. Regarding third-party partners, the Company requires all distributors to sign the *Distributor Compliance Commitment Letter* and all suppliers to sign the *Anti-Unfair Competition Commitment and the Integrity Commitment*, clearly outlining compliance and integrity requirements throughout the collaboration process. Additionally, the Company has further optimized its marketing supplier selection procedures. During the reporting period, the Company conducted annual compliance evaluations for marketing suppliers, covering a total of 10 suppliers, all of which passed the evaluation. This initiative has strengthened the integrity and transparency of the marketing supply chain.

Whistleblowing Management

We are committed to creating an open and transparent workplace, underpinned by robust whistleblowing and whistleblower protection mechanisms. Supported by multiple reporting channels, we rigorously implement our *Workflow for Handling Whistleblowing* and the *Measures for Handling Whistleblowing and Complaints and Protecting Whistleblowers*, thereby reinforcing a workplace atmosphere characterized by fairness, integrity, and well-being. We have established multiple channels, including a telephone hotline, supervisory email, physical mailbox, and website message board, to safeguard the reporting rights of internal employees and external partners, ensuring independent and impartial investigations along with transparent outcomes.

During the reporting period, the Company has not received any reports or encountered any violations related to corruption, bribery, extortion, fraud, or money laundering.

Reporting Channels

Hotline

0571-88610082

Email

jdjb@zyloxmedical.com

Address

No. 270 Shuyun Road, Cangqian Subdistrict, Yuhang District, Hangzhou City

Online Message

https://www.zyloxmedical.com/contact-us

Integrity Culture

Zylox-Tonbridge is rooted in integrity, integrating integrity culture, anti-commercial bribery education, and regular compliance training into our culture and governance system. During the reporting period, in response to external regulatory trends and business practices, the Company continuously improved its training system, with a focus on key areas such as anti-commercial bribery policy interpretation, relevant laws and regulations, and updates to compliance procedures. The Company delivered an average of one training session per month throughout the year for key employee groups, including sales, marketing, business development, market access, R&D, and new employees, as part of its efforts to strengthen a structured and inclusive training system. Additionally, the Company regularly conducted "Anti-Corruption and Anti-Insider Information Training" for directors, supervisors, and senior management, continuously enhancing awareness of integrity in business conduct and capabilities in risk prevention and control. For all employees, we systematically implemented "Anti-Commercial Bribery Compliance Training", consistently reinforcing compliance requirements in job performance and further improving the ability to identify and prevent commercial bribery risks. During the reporting period, the Company achieved 100% training coverage and a 100% assessment pass rate, further embedding integrity and compliance across the organization and supporting the Company's stable operations. At the same time, we leveraged two communication channels— "Compliance Information Express" and "Compliance Culture Comics" —to enhance employees' risk prevention and control awareness. "Compliance Information Express" is sent via email every half month, covering dynamics such as anticorruption, cybersecurity, trade secrets protection, intellectual property compliance, and healthcare policies. "Compliance Culture Comics" are published periodically to highlight non-compliance risks through case studies. Reaching all employees, these communications have effectively strengthened compliance awareness and accountability across the organization.

Company-wide "Anti-Commercial Bribery Compliance Training"

In December 2025, Zylox-Tonbridge organized company-wide Anti-Commercial Bribery Compliance Training through a combination of online learning and assessments, covering all employees. All participants completed the training and passed the assessment, achieving both a 100% completion rate and a 100% pass rate. The training reflected the Company's continued efforts to strengthen integrity and compliance awareness across the organization. Focusing on anti-commercial bribery laws and regulations as well as internal compliance requirements, the program was designed to enhance employees' awareness of integrity in professional conduct, reinforce compliance standards, and further strengthen the cultural foundation for lawful and compliant operations.

2025 Zylox-Tonbridge National Channel Development Forum

The Company has been extending compliance principles into its external cooperation ecosystem. In February 2025 and April 2025, we hosted the "2025 Zylox Medical-National Channel Development Forum" and "2025 Tonbridge Medical- National Channel Development Forum" distribution partner conferences, bringing together about 500 distribution partners nationwide. During the event, through compliance presentations, case studies, and interactive exchanges, we systematically explained compliance policy requirements and integrity management practices. This effectively enhanced our partners' risk prevention awareness and compliance execution capabilities, fostering a collaborative effort to build a healthy, transparent, and sustainable cooperation environment.

Information Security and Privacy Protection

The Company places high importance on information security and personal privacy protection. We strictly comply with laws and regulations such as the *Cybersecurity Law of the People's Republic of China*, the *Personal Information Protection Law of the People's Republic of China* and the *Data Security Law of the People's Republic of China*, and fully implement regulatory requirements such as the *Guiding Principles for Cybersecurity Registration Review of Medical Devices in China*. The Company has established the internal policies such as the *Management System for Personal Information Protection*, the *Trade Secret Protection Management Measures*, and the *Employee Confidentiality Handbook*, to strengthen its policy-based information security management framework and mitigate potential information security risks.

Governance Structure Enhancement

We continuously improve the information security management framework, with the General Manager taking overall responsibility for information security management. The Compliance Department, Legal Department, and IT Department jointly form a cross-departmental coordination mechanism responsible for information security supervision, policy implementation, and technical protection, to ensure the secure operation of data processing, information transmission, and business systems across the Company's operations.

Information Security Safeguards

A legal statement is published on the Company's official website, clearly outlining the guidelines for the use of website information. Simultaneously, a privacy policy is made publicly available, transparently disclosing the methods and scope of personal information collection, storage, usage, and protection to ensure the rights to information and data security of external stakeholders.

Data Security Management

We have newly established an HR Management System to standardize the personal information management, covering the entire process of information application, review, transfer, and archiving. This further strengthens the secure management and compliant flow of personnel data, effectively mitigating risks related to data misuse and leakage.

We consistently strengthen information security and trade secret protection management by building a corporate-wide security culture through comprehensive communication and training mechanisms, continuously enhancing employees' awareness of information security and confidentiality consciousness. During the reporting period, the Company organized training activities for all employees focusing on trade secret protection and information security compliance, helping employees gain a deeper understanding of the importance of information confidentiality and the potential legal liabilities associated with breaches. Simultaneously, we conducted tiered training tailored to the characteristics of different roles. Trade secret protection was included as a mandatory course in the onboarding training for new employees, helping them establish fundamental confidentiality awareness and behavioral norms early in their employment. Additionally, specialized training was provided for key roles involved in core technologies and intellectual property, such as research and development, with a focus on reinforcing the protection of core data, technical materials, and research outcomes. Through continuous efforts in policy communication, interpretation of laws and regulations, and analysis of typical cases, the Company has further clarified employees' responsibilities and obligations in information security and confidentiality management. This guidance ensures that employees handle sensitive information and assets in a standardized manner, effectively reducing the risk of information leakage and continuously strengthening the foundation of the Company's information security protection.

Trade Secret Protection Training

In September 2025, the Company conducted a mandatory quarterly training course on trade secret protection for new employees, covering nearly 30 newly hired staff members. The training provided a structured overview of the "*Employee Confidentiality Handbook*", the "*Trade Secret Protection Management Measures*", and relevant laws and regulations, drawing on typical industry cases to enhance understanding. This effectively strengthened employees' awareness of confidentiality and their understanding of legal responsibilities.

At the same time, the Company has integrated trade secret protection training for R&D personnel into routine management. Nearly 50 R&D staff participated in specialized training that focused on explaining information security in R&D and the management standards for technical materials. Through case studies, the training enhanced awareness of protecting core technologies and supported the protection of intellectual property and innovative outcomes.

Responsible Marketing

Zylox-Tonbridge adheres to responsible business practices and marketing management, strictly complying with relevant laws and regulations such as the *People's Republic of China Advertising Law*, the *People's Republic of China Consumer Rights Protection Law*, the *Medical Device Regulation (EU)*. This ensures that all market promotion activities are conducted under legal, truthful, and transparent premises. In accordance with internal management policies such as the *Zylox-Tonbridge Code of Conduct 3.0*, the *Market Promotion Fee Management System, the Domestic Distributor Management Standards*, the Company systematically regulates marketing practices and brand communication activities. During the reporting period, relevant policy terms were updated, ensuring that all marketing activities comply with industry standards and ethical requirements. In international markets, the Company has updated the *Process Control Procedures for Customer-Related Activities*, clearly defining global marketing compliance standards. In addition, we adhere to the *Zylox Medical Brand Visual Identification Manual* and the *Tonbridge Medical Brand Visual Identity Guidelines Manual*, to ensure consistent use of trademarks and prevent conduct that may infringe consumer rights.

To ensure the authenticity and accuracy of marketing content while avoiding false or exaggerated claims, the Company has established a multi-department review mechanism. This mechanism evaluates promotional materials such as product posters, brochures, demonstration videos, promotional posts, and exhibition materials to ensure that every piece of marketing information complies with legal regulations and industry standards. In international market operations, the Company continuously strengthens compliance management of external communications by implementing a cross-departmental collaborative review system. This system provides a comprehensive review of brand communication and marketing content to ensure that externally disclosed information is truthful, accurate, and properly managed. It also helps protect the Company's brand credibility and supports compliant market operations.

Furthermore, we enhance the compliance awareness and risk prevention capabilities of the marketing team through monthly compliance training and specialized marketing compliance meetings. The training includes appropriate conduct in promotional activities, key points in advertising review, standards for interactions with distributors, and case studies of violations. This ensures that employees accurately understand the legal boundaries and internal codes of conduct in marketing activities. Simultaneously, the Company provides global compliance training to help employees better understand the regulatory requirements and cultural differences across various countries and regions, ensuring that international marketing campaigns align with local industry standards and ethical requirements.

Compliance Training for the Marketing and Sales Team

In February 2025, the Company conducted two specialized training sessions focusing on the latest compliance policy developments under the evolving regulatory environment, for employees from the Marketing and Sales, and the R&D teams. These sessions covered a total of 102 employees. The training emphasized interpreting the latest compliance policy requirements and strengthened risk identification and compliance operation guidance by incorporating real business scenarios. This initiative further enhanced the compliance awareness and risk prevention capabilities of both business teams and the R&D personnel.

Protection of Intellectual Property

Intellectual Property Management

Zylox-Tonbridge adopts a zero-tolerance stance towards any infringement of intellectual property rights. We strictly comply with the intellectual property protection laws and regulations of the countries and regions where we operate. Additionally, we continuously refine our intellectual property management system in accordance with laws such as the *Patent Law of the People's Republic of China* and the *Trademark Law of the People's Republic of China.* In 2025, in accordance with the GB/T 29490-2023 standard, we completed the update and revision of the *Intellectual Property Compliance Management Manual*, focusing on strengthening compliance requirements, expanding the scope of intellectual property coverage, and optimizing the structure to align with internationally recognized frameworks. During the reporting period, the Company successfully obtained GB/T 29490-2023 intellectual property management system certification.

GB/T 29490-2023 Intellectual Property Management System Certification

To mitigate potential patent infringement risks, the Company continuously updates the patent risk avoidance ledger for projects and regularly shares it with the Project Management Department. This ensures that project teams can identify and avoid patent risks during the product development phase. Additionally, the Company maintains an inventory of patent risk avoidance ideas for products, assessing the patent feasibility of innovative concepts to ensure that innovation directions comply with legal regulations and ethical standards.

The Company encourages technological innovation by implementing an intellectual property incentive mechanism. Rewards are distributed in two stages—upon patent application acceptance and upon patent grant—to incentivize innovation among employees. To stimulate innovative thinking within teams, the Company organizes brainstorming activities for project engineers periodically, encouraging cross-departmental communication and collaborative innovation. This approach enhances overall R&D creativity and technological foresight.

Intellectual Property Achievements

By the end of the reporting period, the Company has been granted a total of 148 patents, including 73 invention patents, 70 utility model patents, and 5 design patents. The detailed statistics of intellectual property are as follows:

Item	2025	Unit
Total Patents	148	Piece
Patents granted in 2025	25	Piece
Patent applications in progress	57	Piece
Invention patent applications in progress	54	Piece
Utility model patent applications in progress	3	Piece
Total Trademarks	217	Piece
Trademarks registered in 2025	18	Piece
Total Copyrights	8	Piece
Copyrights approved in 2025	3	Piece

Zylox-Tonbridge Patents Granted in 2025 (Selected)

Enhancement of Intellectual Property Awareness

The Company regards training and communication as important measures to strengthen intellectual property management, continuously enhancing employees' awareness and understanding of intellectual property protection. During the reporting period, we organized a total of six training sessions aimed at enhancing awareness of intellectual property protection. These sessions covered topics such as trade secret, legal fundamentals, patent search skills, and patent litigation practices, helping employees master methods for patent searches, risk identification, and compliance management. Furthermore, the Company actively participates in external professional training and industry standard seminars, drawing on advanced management concepts and international best practices to further enhance its capabilities in intellectual property compliance management and protection.

Enhancing ESG Governance

ESG Governance Structure

The Company has established a three-tier ESG governance structure consisting of the Board of Directors, Senior Management, and ESG Working Group. We have fully incorporated ESG duties into the scope of responsibilities of all levels of the organization, forming a top-down system for coordinated management and execution. This framework is designed to effectively identify and address ESG risks and opportunities, including climate change, while strengthening strategic decision-making and execution synergy to ensure the standardized and orderly implementation of all ESG-related initiatives.

Zylox-Tonbridge ESG Governance Structure

Board of Directors

The Board of Directors is responsible for evaluating and determining ESG management policies and strategies, and supervising ESG issues. It also assumes full responsibility for the Company's ESG strategies and reporting, the regular review of ESG issues and progress in achieving ESG goals, and the review and approval of the annual ESG report.

Senior Management

Senior Management is responsible for establishing ESG management policies, strategies and performance indicators. It performs annual planning, management and supervision on ESG management, and evaluates and determines the risks and opportunities related to ESG issues to ensure that the Company has set up an appropriate and effective ESG risk management system. Besides, Senior Management shall regularly review ESG goals and commitments and report the progress in ESG management to the Board of Directors.

ESG Working Group

ESG Working Group is composed of the Company's major functional departments, and is responsible for executing the Company's ESG management policies, promoting routine ESG practices, preparing the annual ESG report, and reporting the progress in ESG practices to Senior Management.

Stakeholder Communication

The Company places great emphasis on communication and collaboration with all stakeholders and is committed to establishing transparent, open, and long-term mutually trust-based communication mechanisms. We continuously listen to and respond to the demands of stakeholders through multiple channels, incorporating their reasonable feedback into the Company's sustainable development and management practices. This serves as a key basis for optimizing ESG performance and information disclosure. Our primary stakeholders include shareholders and investors, government and regulators, media and non-governmental organizations (NGOs), suppliers, customers, patients, employees and the community.

Stakeholders	Shareholders and Investors	Government and Regulators	Media and NGOs	Suppliers	Customers	Employees	Community
Demands and expectations	• Investment Return • Information Disclosure • Compliance Operation	• Compliance Operation • Tax Compliance • Contribution to Society	• Promotion of Industry Development • Ensuring Compliance Publicity • Delivery of Brand Value	• Fairness and Justice • Win-Win Cooperation	• Contract Compliance and Fulfillment • Honest Operation • High Quality Products and Services • Customer Privacy Protection	• Employee Rights and Interests Protection • Occupational Health and Safety • Employee Benefits Improvement • Equal Opportunities and Diversification	• Active Engagement in Public Welfare • Creating Positive Impacts
Communication channels	• Information Disclosure • Investor briefings • Shareholder meetings • Investor Open Day • Roadshows and reverse roadshows	• Business Communication • Research and Inspection • Policy Implementation	• Information Release • Company's Website • Media Interviews • Press Conferences • Meeting Communication	• Business Communication • Regular Meetings • Field Visits • Assessment and Appraisal	• Business Communication • Customer Feedback • Exchange and Discussion • Negotiation and Cooperation • Customer Satisfaction Survey	• Labor Union • Employee Meetings • Development Training • Performance Assessment • Team Building	• Zylox-Tonbridge Public Charity Special Fund • Community Service • Information Bulletin

"Investor Open Day" Promotes Transparent Communication and Long-Term Trust

In January 2026, Zylox-Tonbridge hosted the Investor Open Day in Zhuhai under the theme "Driving Innovation and Global Expansion", inviting investors and securities analysts for on-site exchanges. The event, through a series of activities such as thematic presentations, product showcases, clinical application interpretations, and production line tours, systematically showcased the Company's innovative achievements in vascular intervention, operational capabilities, and global strategic layout, thereby enhancing transparency in information disclosure and the effectiveness of communication. The Company's management engaged in in-depth discussions with investors on key topics, including operational performance, product pipelines, and globalization strategies, actively responding to investor interest and articulating the Company's long-term development strategy and value creation path.

During the interactive exchanges, we highlighted several approved and in-development innovative products, demonstrating the clinical translation capabilities enabled by "Medical-engineering Integration" in real-world clinical application scenarios. Furthermore, by opening our manufacturing base for visits, we provided investors with a direct and comprehensive understanding of the Company's R&D, manufacturing, and quality management systems. Moving forward, the Company will continue to leverage diverse communication mechanisms to promote transparent information disclosure and engagement, deepen long-term mutual trust relationships with the market, and support the Company in achieving steady and sustainable development.

Materiality Assessment

In order to clarify the focus of ESG practices and information disclosure, and determine our ESG priorities, we regularly collect, analyze, and evaluate the ESG-related topics of concern to stakeholders. This process is based on ongoing communication with stakeholders, referencing the Hong Kong Stock Exchange *ESG Reporting Guide*, national policies and guidelines, industry trend tracking, an analysis of the Company's operational characteristics and strategic direction, as well as ESG focus areas among peers. This enables us to determine the Company's ESG management priorities. The Company's ESG materiality assessment process is as follows:

Step 1: Identify ESG issues

- Review ESG practices and stakeholder feedback
- Benchmark against major concerns in the industry and good practices from peers
- Refer to the criteria for ESG rating

Step 2: Stakeholder communication and research

- Visit external stakeholders
- Interview internal stakeholders
- Prioritize material ESG issues

Step 3: Assessment of material issues

- The Board of Directors, senior management and ESG working group review and confirm the assessment results

During the reporting period, through industry research and topic review, combined with industry development trends, business strategic planning, peer ESG practices, and stakeholder engagement, we conducted a comprehensive analysis of the importance, scope of impact, and management boundaries of the topics. It was confirmed that the current topics continue to reflect the focus of the Company's sustainable development management. The Company plans to systematically conduct a materiality assessment of these topics in the next fiscal year based on changes in internal and external environments. Following prudent evaluation, the results of the Company's material topics have remained stable. The matrix of ESG substantive topics for the Company in 2025 is as follows:

2025 Zylox-Tonbridge ESG Materiality Matrix



Appendix

HKEX ESG Reporting Guide Index

KPI	Description	Section(s)
A1	**Emissions**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issue relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste	Practicing Green Operations
A1.1	The types of emissions and respective emissions data	Practicing Green Operations
A1.2	[Deleted on January 1, 2025]	
A1.3	Total hazardous waste produced and, where appropriate, intensity	Practicing Green Operations
A1.4	Total non-hazardous waste produced and, where appropriate, intensity	Practicing Green Operations
A1.5	Description of emissions target(s) set, and steps taken to achieve them	Responding to Climate Change
A1.6	Description of how hazardous and non-hazardous waste is handled, and a description of reduction target(s) set and steps taken to achieve them	Practicing Green Operations
A2	**Use of Resource**	
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials	Practicing Green Operations
A2.1	Direct and/or indirect energy consumption by type in total and intensity	Responding to Climate Change
A2.2	Water consumption in total and intensity	Practicing Green Operations
A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them	Responding to Climate Change
A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them	Practicing Green Operations
A2.5	Total packaging material used for finished products and, if applicable, with reference to per unit produced	Practicing Green Operations

KPI	Description	Section(s)
A3	**The Environment and Natural Resources**	
General Disclosure	Policies on minimizing the issuer's significant impact on the environment and natural resources	Practicing Green Operations
A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them	Practicing Green Operations
A4	**Climate Change**	
General Disclosure	[Deleted on January 1, 2025]	
A4.1	[Deleted on January 1, 2025]	
B1	**Employment**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare	Ensuring Employee Rights
B1.1	Total workforce by gender, employment type, age group and geographical region	Ensuring Employee Rights
B1.2	Employee turnover rate by gender, age group and geographical region	Ensuring Employee Rights
B2	**Health and Safety**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards	Protecting Health and Safety
B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year	Protecting Health and Safety
B2.2	Lost days due to work injury	Protecting Health and Safety
B2.3	Description of occupational health and safety measures, adopted, and how they are implemented and monitored	Protecting Health and Safety
B3	**Development and Training**	
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities	Empowering Employee Growth
B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management)	Empowering Employee Growth

KPI	Description	Section(s)
B3.2	The average training hours completed per employee by gender and employee category	Empowering Employee Growth
B4	**Labor Standards**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labor	Ensuring Employee Rights
B4.1	Description of measures to review employment practices to avoid child and forced labor	Ensuring Employee Rights
B4.2	Description of steps taken to eliminate such practices when discovered	Ensuring Employee Rights
B5	**Supply Chain Management**	
General Disclosure	Policies on managing environmental and social risks of the supply chain	Building Resilient Supply Chains
B5.1	Number of suppliers by geographical region	Building Resilient Supply Chains
B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored	Building Resilient Supply Chains
B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored	Building Resilient Supply Chains
B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored	Building Resilient Supply Chains
B6	**Product Responsibility**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress	Strengthening Quality Control Adhering to Compliance Operation
B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons	Strengthening Quality Control
B6.2	Number of products and service-related complaints received and how they are dealt with	Strengthening Quality Control
B6.3	Description of practices relating to observing and protecting intellectual property rights	Adhering to Compliance Operation
B6.4	Description of quality assurance process and recall procedures	Strengthening Quality Control

KPI	Description	Section(s)
B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored	Adhering to Compliance Operation
B7	**Anti-corruption**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering	Adhering to Compliance Operation
B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases	Adhering to Compliance Operation
B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored	Adhering to Compliance Operation
B7.3	Description of anti-corruption training provided to directors and staff.	Adhering to Compliance Operation
B8	**Community Investment**	
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests	Building a Better Community Together
B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs, health, culture, sport)	Building a Better Community Together
B8.2	Resources contributed (e.g. money or time) to the focus area	Building a Better Community Together

Climate-Related Disclosure Requirements	Description	Section(s)
Governance	(a) The governance body responsible for overseeing climate-related risks and opportunities	Responding to Climate Change
	(b) The role of management in the governance processes, controls, and procedures used to monitor, manage, and oversee climate-related risks and opportunities	Responding to Climate Change
Strategy	Climate-related risks and opportunities	Responding to Climate Change
	Information on business models and value chains	Responding to Climate Change
	Strategy and decision-making	Responding to Climate Change
	Financial position, financial performance, and cash flows	Responding to Climate Change
	Climate resilience	Responding to Climate Change

Climate-Related Disclosure Requirements	Description	Section(s)
Risk Management	(a) The processes and related policies used by the issuer to identify, assess, prioritize, and monitor climate-related risks and opportunities	Responding to Climate Change Adhering to Compliance Operation Enhancing ESG Governance
	(b) The processes used by the issuer to identify, assess, prioritize, and monitor climate-related risks and opportunities (including how the issuer may and does use climate-related scenario analysis to determine climate-related opportunities); and	Responding to Climate Change Adhering to Compliance Operation
	(c) How and to what extent the processes for identifying, assessing, prioritizing, and monitoring climate-related risks and opportunities are integrated into the issuer's overall risk management processes	Responding to Climate Change Adhering to Compliance Operation
Metrics and Targets	Greenhouse gas emissions	Responding to Climate Change
	Climate-related transition risks	Responding to Climate Change
	Climate-related physical risks	Responding to Climate Change
	Climate-related opportunities	Responding to Climate Change
	Capital allocation	Responding to Climate Change
	Internal carbon pricing	Not yet implemented. The Company will closely monitor relevant developments in the industry.
	Compensation	Responding to Climate Change
	Industry-specific metrics	No disclosure currently. The Company will further assess the applicability and feasibility of data collection for cross-industry and industry-specific metrics.
	Climate-Related Targets	Responding to Climate Change

GRI Standards Index

GRI Standards	Disclosure Title	Section(s)
GRI 2: General Disclosures 2021	2-1 Organizational details	About Zylox-Tonbridge
	2-2 Entities included in the organization's sustainability reporting	About This Report
	2-3 Reporting period, frequency and contact point	About This Report
	2-6 Activities, value chain and other business relationships	About Zylox-Tonbridge
	2-7 Employees	Ensuring Employee Growth
	2-9 Governance structure and composition	Strengthening Corporate Governance
	2-10 Nomination and selection of the highest governance body	Strengthening Corporate Governance
	2-11 Chair of the highest governance body	Strengthening Corporate Governance
	2-12 Role of the highest governance body in overseeing the management of impacts	Enhancing ESG Governance
	2-13 Delegation of responsibility for managing impacts	Enhancing ESG Governance
	2-14 Role of the highest governance body in sustainability reporting	Enhancing ESG Governance
	2-15 Conflicts of interest	Adhering to Compliance Operation
	2-16 Communication of critical concerns	Enhancing ESG Governance
	2-17 Collective knowledge of the highest governance body	Enhancing ESG Governance
	2-19 Remuneration policies	Ensuring Employee Growth
	2-23 Policy commitments	Ensuring Employee Growth Green Operations Adhering to Compliance Operation
	2-24 Embedding policy commitments	Ensuring Employee Growth Green Operations Adhering to Compliance Operation

GRI Standards	Disclosure Title	Section(s)
GRI 2: General Disclosures 2021	2-25 Processes to remediate negative impacts	Adhering to Compliance Operation
	2-26 Mechanisms for seeking advice and raising concerns	Enhancing ESG Governance
	2-27 Compliance with laws and regulations	Adhering to Compliance Operation
	2-28 Membership associations	Reinforcing the Foundation for Innovation
	2-29 Approach to stakeholder engagement	Enhancing ESG Governance
	2-30 Collective bargaining agreements	Ensuring Employee Growth
GRI 3: Material Topics 2021	3-1. Guidance to determine material topics	Enhancing ESG Governance
	3- 2. Disclosures on material topics	Enhancing ESG Governance
	3-3 Management of material topics	Enhancing ESG Governance
GRI 201：Economic Performance 2016	201-1 Direct economic value generated and distributed	About Zylox-Tonbridge
	201-2 Financial implications and other risks and opportunities due to climate change	Responding to Climate Change
	201-3 Defined benefit plan obligations and other retirement plans	Ensuring Employee Growth
GRI 203：Indirect Economic Impacts 2016	203-1 Infrastructure investments and services supported	Building a Better Community Together
GRI 205：Anti-corruption 2016	205-2 Communication and training about anti-corruption policies and procedures	Adhering to Compliance Operation
	205-3 Confirmed incidents of corruption and actions taken	Adhering to Compliance Operation
GRI 206：Anti-competitive Behavior 2016	206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	Adhering to Compliance Operation
GRI 301：Materials 2016	301-1 Materials used by weight or volume	Green Operations

GRI Standards	Disclosure Title	Section(s)
GRI 302：Energy2016	302-1 Energy consumption within the organization	Responding to Climate Change
	302-3 Energy intensity	Responding to Climate Change
GRI 303：Water and Effluents 2018	303-1 Interactions with water as a shared resource	Green Operations
	303-2 Management of water discharge-related impacts	Green Operations
	303-3 Water withdrawal	Green Operations
	303-4 Water Discharge	Green Operations
	303-5 Water Consumption	Green Operations
GRI 305：Emissions 2016	305-1 Direct (Scope 1) GHG emissions	Responding to Climate Change
	305-2 Energy indirect (Scope 2) GHG emissions	Responding to Climate Change
	305-4 GHG emissions intensity	Responding to Climate Change
GRI 306：Waste 2016	306-1 Waste generation and significant waste-related impacts	Green Operations
	306-2 Management of significant waste related impacts	Green Operations
	306-3 Waste generated	Green Operations
GRI 308：Supplier Environmental Assessment 2016	308-1 New suppliers that were screened using environmental criteria	Building a Resilient Supply Chain
	308-2 Negative environmental impacts in the supply chain and action taken	Building a Resilient Supply Chain
GRI 401：Employment 2016	401-1 New employee hires and employee turnover	
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	Creating a Positive Workplace Environment
	401-3 Parental leave	Ensuring Employee Rights
GRI 403：Occupational Health and Safety 2018	403-1 Occupational health and safety management system	Protecting Health and Safety
	403-2 Hazard identification, risk assessment, and incident investigation	Protecting Health and Safety
	403-3 Occupational health services	Protecting Health and Safety
	403-4 Worker participation, consultation, and communication on occupational health and safety	Protecting Health and Safety

GRI Standards	Disclosure Title	Section(s)
GRI 403：Occupational Health and Safety 2018	403-5 Worker training on occupational health and safety	Protecting Health and Safety
	403-6 Promotion of worker health	Protecting Health and Safety
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	Protecting Health and Safety
	403-8 Workers covered by an occupational health and safety management system	Protecting Health and Safety
	403-9 Work-related injuries	Protecting Health and Safety
	403-10 Work-related ill health	Protecting Health and Safety
GRI 404：Training and Education 2016	404-1 Average hours of training per year per employee	Empowering Employee Growth
	404-2 Programs for upgrading employee skills and transition assistance programs	Empowering Employee Growth
GRI 405：Diversity and Equal Opportunity 2016	405-1 Diversity of governance bodies and employees	Ensuring Employee Rights Strengthening Corporate Governance
GRI 406：Non-discrimination 2016	406-1 Incidents of discrimination and corrective actions taken	Ensuring Employee Rights
GRI 407：Freedom of Association and Collective Bargaining 2016	407-1 Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	Ensuring Employee Rights
GRI 408：Child Labor 2016	408-1 Operations and suppliers at significant risk for incidents of child labor	Ensuring Employee Rights
GRI 409：Forced or Compulsory Labor 2016	409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor	Ensuring Employee Rights
GRI 416：Customer Health and Safety 2016	416-1 Assessment of the health and safety impacts of product and service categories	Strengthening Quality Control
	416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	Strengthening Quality Control
GRI 417：Marketing and Labeling 2016	417-1 Requirements for product and service information and labeling	Adhering to Compliance Operation
GRI 418：Customer Privacy 2016	418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data	Adhering to Compliance Operation

ZYLOX TONBRIDGE

INNOVATION FOR QUALITY LIFE

ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Zylox-Tonbridge Industrial Park, No. 270 Shuyun Road, Yuhang District, Hangzhou, Zhejiang Province, China
www.zyloxtb.com